Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tamar Thompson, Head of Global Corporate Affairs at Alexion, AstraZeneca Rare Disease.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology space with Tamar, covering:

• The epidemiological challenge of rare diseases and representing the topic at the White House
• Why is rare disease drug development so hard, but why is there so much interest in the area given the tech advancements?
• The value and impact of an acquisition for mid-sized biotech by pharma giant AstraZeneca
• Some top tips from the perspective of being a minority, female leader in the industry... and the importance of finding your champions

Tamar leads global corporate affairs and is responsible for communications, government affairs, and policy for Alexion. In addition, she serves as Chairwoman of the Board for Alexion’s charitable foundation and the Alexion lead for Inclusion and Diversity. 

Before Alexion, Tamar led Federal Executive Branch Strategy and State Government Affairs for Bristol-Myers Squibb. Tamar has more than 20 years of progressive healthcare experience spanning across several industry sectors.

Tamar holds a M.S. in Health Sciences with a concentration in Public Health from Trident University. Tamar also serves as Chair at MassBio, is on the board of directors for the Boston Chamber, and sits on the Schwartz Center (MassGeneral Hospital) Leadership Council.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Garabedian, CEO at Xontogeny and Venture Fund Manager at Perceptive Advisors.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:

• How he utilized his pharma experience to become a CEO and revitalize a biotech company, positioning it for a $15bn market cap
• Why the biotech space had such a market downturn, and how the uptake in the industry will be data-driven
• Demystifying the role of a biotech CEO and understanding what it takes to drive successful drug development
• Why relying on outsourcing is critical for biotechs today
• The emerging, secondary-tier biotech clusters in the US... but why does Boston remain unrivalled?

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and is Portfolio Manager of the Perceptive Xontogeny Ventures Fund, which supports early-stage companies with Series A investments across biotech, medtech and healthtech.

Chris has a broad base of experience and a track record of success over his decades-long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial-stage leader in the genetic technology space. He also led Corporate Strategy for Celgene from 2007 to 2010 and served in several global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

He serves on the boards of several life sciences companies and speaks at industry conferences on a wide range of important issues. He is a member of the Corporate Relations Board for the Keck Graduate Institute. He has previously served on the Board of Directors of MassBio and is a Senior Advisor for the Boston Consulting Group.

-----

Join Molecule to Market and ramarketing for an exclusive panel discussion series at this year's CPHI Milan - across 3 power-packed sessions, our industry experts will be sharing insights into driving brand growth with strategic marketing.

Find out more and pre-register here

-----

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kent Payne, CEO at Aliri Bioanalysis.

 Your host Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kent, covering:

• Being exposed to scientific efficiencies early on in his career as a bench scientist, and what it took to bring a successful NDA to market
• The formative years of Catalent, and helping to establish its early biologics and bioanalysis capabilities
• He shares his core principles playbook for getting a company back on track and on a path for growth
• The value of getting scientists in front of the client to build relationships and demonstrate technical know-how
• The strong fundamentals that attracted him to Aliri, and having hot RNA therapeutic capabilities to offer the market
• How Aliri was formed through the merger of three well-established players in the bioanalytical space: Tandem Labs, Pyxant Labs, and ImaBiotech

 Dr. Kent Payne is distinguished as a business operator and leader in sales, commercial manufacturing, and product development. He has extensive executive experience in M&A and successfully running start-up, growth, and turnaround businesses in Fortune 500 and Private Equity environments. Kent currently serves as the CEO of Aliri Bioanalysis (an Archimed investment company) and board director for GBI (a Signet Healthcare Partners company). He previously served as the CEO of BioDuro-Sundia, LLC (an Advent International company)

Aliri Bioanalysis is celebrating the 30th anniversary of its operations in Salt Lake City, Utah, which coincidently, is also the location of the AAPS annual meeting this year.  Kent and team are marking this special occasion during the conference where they will showcase their technical expertise with over a dozen scientific posters and presentations.  He also wanted to let our listeners know that his team would be happy to host personal tours of their lab in Salt Lake to those attending the conference.  Simply email [email protected] to learn more.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gil, covering:

• The evolution of the PBOA over the last decade, the impact of M&A on the Association, and building a safe place where CDMOs belong
• How the industry has evolved over the last few years after Covid, including harder times and areas of green shoots
• Why Gil believes Novo's purchase of Catalent is a black swan event and not a new megatrend
• A deeper dive into fine details of The BIOSECURE Act, and its potential impact on the CDMO space over the next 7-8 years
• The need to know market headwinds and tailwinds that you simply cannot ignore

Gil Roth is the Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA), a nonprofit trade group that advocates for the regulatory, legislative and general business interests of the CMO/CDMO sector. In this role, he brings CDMO perspectives and education to FDA, the US Congress, and other bodies, and brings CDMOs together to share best practices, develop policy positions, and provide briefings on government positions that impact that sector. He also organizes and hosts PBOA's annual members-only Meeting & Conference.

Previously, he was the Founding Editor of Contract Pharma magazine. In his alleged free time, he produces a weekly cultural conversation podcast called the Virtual Memories Show (https://chimeraobscura.com/vm)

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steven Chevillotte, Chief Executive Officer at SaniSure.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steven, covering:

• Building a great partner through professionalization and integration while retaining founder DNA of entrepreneurship and innovation
• The transformation of quality components and complex assemblies to game changing systems and solutions
• How SaniSure differentiates from smaller and larger bioprocessing organizations
• Why exceptionally robust and clean products coupled with excellence in customized components and designing flow paths make SaniSure the partner of choice for Advanced Therapies (Eg: Cell Therapy)
• Making the bioprocessing supply chain more robust

SaniSure CEO Steven has held senior leadership roles in finance, operations, and general management at precision manufacturing businesses, always in highly engineered and highly regulated industries, including Class III Medical Devices and Aerospace & Defense. Has learned best practices at large public and private companies and has developed an expertise and passion for hands-on transformation through strategy deployment. He is experienced with M&A and integration in PE-backed environments and has led a successful exit process. Steve holds Masters degrees in Manufacturing Systems Engineering and Financial Analysis & Accountancy.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping comp

In this mid year episode special, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the trends happening across the life sciences and outsourcing space in 2024. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain covering: 

• The anticipated recovery of the biotech sector and where it stands now
• Geopolitical influences on the life sciences industry, with a focus on the CDMO sector
• Exciting upcoming episodes and insights to watch for in the next few weeks
• Where to meet Raman at upcoming trade shows across North America & Europe
• Sectors powering through industry challenges, including early-stage development and AI-driven drug discovery

Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Yussuf Goolam, Co-Founder, President and CEO at RxSource.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Yussuf, covering:

• His family's journey from Mozambique to North America and the value of having an entrepreneurial ethos
• Lifelong business lessons from a window cleaning job... and the impact of going on a learning rampage
• The real-life grind of getting a business off the ground and always being willing to chase an opportunity
• The pivot that led to becoming a global partner for clinical trial supplies and not just a transactional sourcing supplier
• The importance of purpose, mission, values, culture and clarity in building a fiercely loyal and fulfilled workforce
•  

After co-founding RxSource in 2005, Yussuf’s initial focus was developing and expanding the company’s brand and client base globally. In early 2020, he assumed a new role as President and CEO and guided the organisation through a significant transformation. Since shifting the focus to clinical trial supply chain services, the company has grown to over 60 team members worldwide, supporting CROs, biotechs, and sponsors.

With over 20 years of experience in the niche pharmaceutical sector, he is dedicated to building a purpose-driven company by supporting a team of high-performing individuals to achieve their personal and professional goals together.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Cook, CEO at Sterling Pharma Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:

• Decades of mixed ownership and conflicting business models led to lots of character-building learnings... and the rebirth of Sterling
• The power of a rebrand and sense of togetherness to gain commercial traction
• Kevin’s five-point M&A playbook that’s helped drive exponential, transatlantic growth
• Why culture and people are the hardest things when scaling from 180 colleagues on one site to a 1300+ strong team across six sites
• The robustness of small molecules, on-shoring back to the West and reasons to be optimistic for the future

Kevin has over 30 years of experience in the pharmaceutical industry. He started working with Robinson Brothers as an Assistant Plant Manager before progressing to Senior Plant Manager. Kevin then joined Boots Pharmaceuticals with responsibility for commissioning activities on a new pharmaceutical plant.

In 1993 Kevin joined Sterling Organics and has supported the site through several mergers and acquisitions over 18 years. At that time, he was Operations Director for Chirex, Industrial Director for Rhodia Pharma Solutions, and President of Shasun Pharma Solutions.

In 2010, Kevin joined Aesica Pharmaceuticals as the Managing Director for the API business unit with a clear focus on growth through increasing the customer and product portfolio. Kevin returned to Shasun Pharma Solutions in 2013 to take responsibility for all commercial activities relating to the pharmaceutical service business. Having overseen the launch of Sterling Pharma Solutions as an independent CDMO, he was appointed CEO, President, and Board Member.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vijay Vaswani, Co-Founder & CEO at Omniscope.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vijay, covering:

• How travel expands the mind and enables you to amplify your network
• The founding story of Omniscope and its mission of using tech to help unlock the immune system
• AI can read the immune system in HD, helping with clinical trials and predictive candidate selection
• How you should be thinking about AI for drug discovery and drug development
• And what the t-shirt he wears at work says on the front...

Vijay Vaswani views technology as fundamental to humanity. He has been involved in scaling companies such as Illumina and 10X Genomics. During his leadership at Siemens Healthineers and Meridian Biosciences, he acquired and commercialized disruptive diagnostic technologies. Vijay has also participated in important IPOs in the biotechnology industry and finds his passion in improving health through the application of technology.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

See you at BPI!

M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://informaconnect.com/bioprocessinternational/?vip_code=MOLECULE30&utm_source=molecule2market&utm_medium=website

Don't miss out and we'll see you in September!

In this episode of Molecule to Market, you’ll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Why being a supplier is harder if you have not been on the client side
• An industry driven by change and the importance of digital strategy to drive business outcomes
• Why pharma companies need to be both big and fast to win
• How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks
• The future of deployable, modular factories to service population centers that provide better access to personalized medicines
• How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots’)

David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing & supply.

In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master’s Programmes.

LinkedIn: (6) David Staunton | LinkedIn

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOne
• Hanna Lesch, Chief Technology Officer at Exothera 
• Stephen Grant, entrepreneurial advisor and angel investor

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering:

• Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implications
• Will the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing?
• How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE Act
• What impacts BIOSECURE will have on the supply chain 

The BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mihaela Simianu, Vice President of R&D and Operations at Singota Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mihaela, covering:

• How having physician parents in Romania motivated Mihaela into a career in the biopharmaceutical space
• What 17 years at Eli Lilly taught her about drug development and commercialization... and why she ultimately left for Amgen
• Why, after 25 years on the drug sponsor-side, she opted to move onto the CDMO side
• The rapid, complex, and fascinating experience of being part of a small CDMO that supports multiple sponsors to serve patients
• The advisory and execution role of a CDMO partner

Dr. Simianu is a transformational leader in the biopharmaceutical industry, renowned for advancing technology and therapeutic products to enhance personalized medicine and public health. She has achieved significant outcomes for multi-billion-dollar organizations, leading to the approval of 20+ new therapeutic agents and the introduction of commercial processes at more than thirty manufacturing sites globally across her tenure with Eli Lilly, Amgen, and Merck.

Her expertise spans multiple disease areas, and she excels in integrating raw material suppliers, facilities, and engineering equipment into pharmaceutical systems. Specializing in modern product development, quality, and manufacturing systems, she has played a pivotal role in injectable drug commercialization and market expansion. She advanced a portfolio of over thirty-five new pipeline products.

Dr. Simianu holds a Ph.D. in Chemistry from Marquette University, an M.S./B.S. in Chemical Engineering from the Babes-Bolyai University of Cluj-Napoca, and a Jack Welch Management Institute certification. She is a recognized international industry expert and has actively volunteered for the Parenteral Drug Association for over 20 years.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Doctor Eric Edwards, Co-Founder and CEO at Phlow.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Eric, covering:

• How a life-threatening allergy for him and his identical twin brother led to a career in medicine and then an entrepreneurial journey in the pharma space
• The journey from inventors to becoming a commercial pharma company... followed by a $310m exit
• How a plan to support a shortage in critical medicines for children took a turn as the COVID-19 pandemic arrived
• The US Government awarded a $899m contract to help rebuild the domestic industrial base for Covid medicines and longer-term advanced manufacturing
• The paradox of innovative, specialty, expensive medicines vs. drug shortages for basic essential medicines that everyone should be able to access

As CEO, Eric has assembled a world-class team committed to providing a solution to the broken essential medicines supply chain and the overreliance on foreign manufacturers for the US' highest priority medicines.

He previously co-founded Kaléo, where he held several executive management positions, including Chief Science Officer, Chief Medical Officer, and Vice President.

Dr. Edwards is the co-inventor of multiple marketed products for treating allergic emergencies (anaphylaxis), named on over 215 issued and patent-pending applications.

As a Doctor of Medicine and a Biology Ph.D. in Pharmaceutical Sciences, Eric also continues to serve his community by volunteering on a local rescue squad. This includes responding to 911 calls and training paramedics in pre-hospital emergency care.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andy Holt, CCO of Viralgen Vector Core.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andy, covering:

• Growing a CDMO while dealmaking in a gene therapy company…at the same time
• Selling a revenue-generating therapy company to Bayer during the pandemic
• Faster failure or faster acceleration; the need to celebrate every gene therapy batch as it’s going to save lives
• The challenges of manufacturing AAV gene therapies and why the next generation of CGT CDMOs need a voice at the table 

Andy has been working on the business side of cell and gene therapy for more than 15 years, focused on creatively connecting science and solutions, whether health care for whale sharks or supporting multi-billion dollar transactions between biotech and big pharma. 

Along the way, he has held positions in business development and management for several large CDMOs like Lonza and MilliporeSigma, leadership positions in Askbio, Ncardia, and Cellistic, and his current role as Chief Commercial Officer for Viralgen, a pioneering AAV-focused CDMO leveraging Askbio’s manufacturing expertise for clients around the world.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark W. Womack, Chief Executive Officer at BioCina.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:

• How a tough upbringing in LA led him to the US Navy, and then onto a pathway into leadership
• Why he decided to end his own practice and jump into a senior role within a biopharma CDMO space
• The key factors that led him to relocate to Adelaide, Australia
• The reality that most biologics CDMOs frequently fail to deliver... and why winning requires operating with discipline, and consistently executing at a high level

Mark W. Womack is BioCina’s Chief Executive Officer. Prior to BioCina, he was CEO of KBI Biopharma and Selexis SA, and previous to that, he was CEO and Managing Director of Stelis Biopharma, leading both to significant YOY growth. Preceding Stelis, as the CBO for AGC Biologics, one of the world’s leading global biopharma CDMOs, he led them to nearly a 300% increase in new sales in just two years.

Prior to joining AGC Biologics, Mark served over 20 years as an international management consulting industry leader, guiding many of the world’s renowned companies to achieve record highs in revenue and profit. This included a $20B post-merger integration within General Motors and numerous transformations that generated more than $100M in certified client benefits.

Mark began his professional journey by leading a succession of U.S. Navy units to unprecedented results, including while serving as a combat center leader on a destroyer class ship, and he received numerous of the Navy’s highest honors and awards.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bill Vincent, Founder and board chair at Genezen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:

• The days when CGT therapies were viewed as just academic... then the events in 2012 that changed everything in the space
• How partnering with Indiana University for its vector capacity led to the creation of Genezen
• Building a team that had been trained really well... by his wife!
• Looking for a PE company that brings more than just a fat cheque
• What’s next for the CGT sector after an over-hyped few years of fundraises... and what areas could be hot in the future

Bill is the board chair of Genezen, a biotech contract manufacturer of viral vectors, cell manufacturing, and testing services. He founded the company fourteen years ago and grew it from his one-person operation to its current 60 employees with an outside investment of $45 million. He has spent the last 35 years working in the consumer products, pharma, and biotech sectors.

Prior to Genezen, Bill was President and CEO at Rimedion, a gene therapy company developing treatments for rare genetic disorders. He currently serves on the board of Cellular Engineering Technologies, a stem cell services company.

Bill discovered a passion for entrepreneurship through his exposure to new business development opportunities in a corporate setting. Upon completing his MBA at the University of Texas, he participated in a two-year executive development program with Philip Morris.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Helen Shaw and Dan Henley, co-founders of VCTC.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Helen and Dan, covering:

• Exposing your team to everything, letting them feel the pressure... but always being there to help and guide
• The founding story of VCTC... and the fun and games of dividing responsibilities as co-founders
• How the frustrations of being a patient with an orphan disease shaped the ethos of VCTC
• The uptake of patient recruitment and retention in virtual and decentralized clinical trials
• Finding a powerful niche in the life sciences space to enable you to grow, globally

Helen and Dan are co-founders of the VCTC, a UK clinical trial site that specializes in delivering virtual and decentralized clinical trials.

Helen has fourteen years of clinical research experience spanning academia, clinical trial sites, biotech and CRO, with exposure across study management, medical writing, clinical science, and commercial roles.

Dan is a senior executive bringing 15 plus years of comprehensive achievements in predominantly commercial roles supporting biotechnology, pharma and life sciences companies, through their non-clinical, clinical and commercial journeys.

The VCTC is a UK-based clinical trial site that specializes in running patient-centric clinical trials. We bring virtual and decentralized clinical trials to participants in their own homes.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bill Humphries, CEO at Alcami.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:

• The role managers, leaders, and mentors have played in shaping his illustrious career in dermatology
• The importance of ‘force multiply’ in getting results and accelerating growth
• Why, after a career spent on the drug sponsor side... he decided to switch to the CDMO services side
• How do the shifting sands in the sector provide a treasure trove of opportunities?

Bill Humphries, Alcami CEO, is an experienced leader in the life sciences industry, previously serving as CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals. 

Bill also served as Chairman of the Board at Clearside Biomedical, Executive Chairman of Strata Skin Sciences, and a member of the Board of Directors at Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals. Humphries’ academic credentials include a B.A. from Bucknell University and an MBA from Pepperdine University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector for part 2 of our conversation with Thomas Eldered, Executive Chairman at Flerie.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• The story behind Recipharm’s decision to divest Cobra Biologics that led Thomas to become owner
• How ‘big faith’ and the gene therapy revolution changed the fortunes of the loss-making biologics CDMO
• After the third exit, why did he choose ‘passion rather than pension’? To fuel his love for creating things and building companies
• Flerie’s mission and its patient-centric investment strategy in life sciences.
• The story behind Thomas’ signature bowtie look…

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries.

He was also the founder of Flerie Invest AB in 2011, where he is currently the executive chairman. Thomas is presently chairman of the board and a member of the board of several life science companies. He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with part 1 of our episode with Thomas Eldered, Executive Chairman at Flerie.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• Where his entrepreneurial spark originated, and how they created a CMO (before that was even a thing) after several failed plans
• How did the timing of his first exit and having ‘cash during the crash’ fuel M&A to grow Recipharm into an international powerhouse?
• Why did he decide to go public? No one else in Sweden or in the CDMO space was getting an IPO
• A lifetime with Lars (his business partner) and the benefit of a partnership with aligned common interest
• Why he decided to sell Recipharm after 26 years and why leaving the company was the most difficult mental decision

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries. He also founded Flerie Invest AB in 2011, where he is currently Executive Chairman. Thomas is currently chairman of the board and a member of the board of several life science companies. 

He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dan Mamelak, Founder & President at Custom Biologics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:

• How reading The Billion-dollar Molecule book inspired him to explore a pathway into cutting-edge drug development
• The founding story of his company and some timeless advice not to burn bridges
• How the Canadian conveyor belt of intelligent, talented young science graduates has helped fuel the company’s growth
• Why being privately owned has contributed to the company’s unique culture

Dan is responsible for the company's strategic direction. From the outset of his career, Dan recognized the need for solid bioanalytical expertise to support the drug discovery programs of both developing and established biopharmaceutical companies.

In 2004, Dan established Custom Biologics, a large-molecule bioanalytical CRO that designs and validates assays to measure the potency of biotherapeutic drugs, including therapeutic monoclonal antibodies and genetic therapies. Recently, the Genomics division of Custom Biologics has developed novel isothermal nucleic acid molecular diagnostic tests to rapidly identify human and food-borne pathogens.

Before founding Custom Biologics, Dan was a Senior Scientist at Affinium Pharmaceuticals, an established company that accelerates the development of small molecules into new medicines. Dan holds a Ph.D. in Biochemistry from the University of Toronto.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with: 

• Denise Bowser from Onyx Scientific
• Audrey Greenberg from SK Pharmteco
• Kendalle Burlin O’Connell from MassBio
• Elisabeth Stampa from Medicines For Europe 
• Sabina Ouimet-Storrs from GHO Capital

In this episode, we feature highlights from recent interviews with some of the most inspiring women in the life sciences industry. These women sat down with host, Raman Sehgal, to share their unique perspectives on topics including career progression, COVID-19, M&A, and the importance of diversity and inclusion in the workplace.

Listen to the full episodes: 

• Dealing with downturns… and the menopause with Denise Bowser
• From banking to biotech with Audrey Greenberg 
• From MassBio… to the world with Kendalle Burlin O’Connell 
• Transforming a family pharma firm with Elisabeth Stampa 
• M&A Roundtable and 2024 Predictions with Sabina Ouimet-Storrs

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alastair Hay, Vice President of Peptides at Almac Sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alastair, covering:

• The story behind Almac’s early bet of getting into the peptide game
• Behind the scenes of the incredible growth journey of Almac from a few hundred to 7000+ people... and some insight into the secret sauce behind the success
• Rising demand for peptides and what makes them so attractive and valuable for various emerging therapeutic areas
• Some of the challenges in developing and manufacturing peptide-based therapeutics include environmental impact

Alastair graduated with a Ph.D. in synthetic organic chemistry from the University of Edinburgh in 1998, following his first degree in Pure and Applied Chemistry at the University of Strathclyde.

He spent 12 years on the operational side of Almac’s peptide business, heading up the non-GMP custom synthesis group and then the GMP process development group. In 2015, Alastair moved on from an operational role to provide technical support on peptide projects for Almac’s global business development team.

In 2020, Alastair took on operational responsibilities, first re-assuming leadership of the Process Development department and then ultimately being appointed Vice President, Peptides in 2021.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Brett Alderson, President and Site Leader of Novacina.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Brett, covering:

• The complexities of being on the inside of big pharma looking to carve out your site... then transitioning into a customer-facing CDMO
• Leaning into the freedom and liberation of having the shackles off as an independent business
• Pairing world-class, complex commercial capabilities (100 million+ units) with a small scaler clinical offering
• The uncertainty and capacity concerns on the market after that market-shaking deal
• And just why Australia is a hub for global for clinical trials...

Brett Alderson is a seasoned veteran in the pharmaceutical industry predominantly working with the manufacturing of sterile injectables. Brett is a determined and thoughtful leader adept at driving business success and leading through change. He is a champion for customers, instilling a customer-centric culture with transparency and helpfulness. 

He enjoys mentoring and nurturing a diverse workforce with a clear imperative of open and honest communication. Brett has a reputation as an energetic problem solver, acting with integrity and care, and always encourages solutions for a brighter tomorrow by empowering people.

Brett’s career includes more than 25 years at Pfizer, before becoming President and Site Leader of Novacina in April 2023 where he oversaw a 500-member team and the production of more than 300 Oncology products plus several additional sterile injectable medicines for local and global markets.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Arvid Söderhall, CEO at Empros Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Arvid, covering:

• The personal story of a pediatrician treating an obese child that led to the creation of Empros Pharma and its lead asset
• The 10-year journey from an idea to a successful Phase IIb trial... and what it felt like to reach the magic milestone
• Critical characteristics required for a small pharma leader, and why CEOs stand and fall with their data
• The ins and outs of a CDMO selection process for Phase 3 trials and the commercial launch for a global drug to complement GLP-1 products
• How the investor climate has changed in the last 1-2 years... and how it has it turned upside down in the hot obesity space

Arvid joined Empros as a project manager in 2013, during the company’s foundational phase, before the EMP16 project was named. He quickly ascended to CEO, steering Empros to prioritize its founders and inventors while leveraging a strong network of contacts and leading Empros to a phase 3-ready project that surpassed initial expectations.

He holds a Ph.D. in Physical Chemistry with a specialization in Computational Chemistry. He then completed a postdoctoral fellowship in Berlin, marking his first engagement with the pharma industry and filing a first patent, introducing a foray into biotech entrepreneurship. Subsequently, Arvid worked at Stockholm-based biotech ‘Sidec,’ focusing on cryo-electron microscopy of proteins. Despite the premature technology leading to Sidec’s closure, the foundational concept later earned a Nobel Prize, underscoring the importance of timing in innovation.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Sabina Ouimet-Storrs, Principal at GHO Capital Partners
• James West, Managing Director at Lincoln International
• Derek Hennecke, investor and board member in biopharma and cell therapy manufacturing

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests, covering:

• The year of the failed process in 2023...
• Which sub-segments of the pharma services ecosystem are hot right now?
• A myriad of buys and builds, carve-outs, and platform deals
• An optimistic outlook for the year ahead... despite some significant market headwinds

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Elisabeth Stampa, President Medicines for Europe and Board Chair at Medichem.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Elisabeth, covering:

• She took the reigns of the family pharmaceutical firm from her father
• The struggle of turning around the business through rationalization and divestment and critical lessons learned from a tricky time
• Re-building into a multi-national, $140m+ API and FDF CDMO with flexibility at its core
• Insights into future trends will impact our space, including the aging population, reliance on Asia, and the need for patient affordability to access medicines

With over twenty years in the industry and an experienced business leader with a track record in growing and transforming businesses, Elisabeth serves on the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player.

A pharmacy graduate by trade, she also serves on the Board of Trustees at the IQS in Barcelona and is President Medicines for Europe. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry globally.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kendalle Burlin O’Connell, CEO and President of MassBio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kendalle, covering:

• The story behind how Massachusetts became one of the biggest biotech clusters in the world and why this ecosystem has such an energy
• Kendalle’s non-linear journey into MassBio and how she made an impact (and ruffled some feathers)
• How she navigated her way to the top of MassBio, including lessons learned along the way and dealing with her inner voice
• Her optimistic sentiment for 2024 and the broader impact on global life sciences

Kendalle leads the organization's strategic direction and drives policy advocacy for the industry to ensure that Massachusetts life sciences companies have the best environment possible to research, develop, manufacture, and commercialize breakthrough therapies and cures for people worldwide. Pursuing innovation and delivering for members are the hallmarks of Kendalle’s more than 15 years at MassBio, including the launch of several multi-year initiatives focused on realizing a diverse and equitable life sciences industry, supporting the continued growth and sustainability of the sector throughout Massachusetts, and providing resources and solutions to companies across the industry value chain.

A lawyer by trade, she has earned a spot on the Boston Business Journal’s 2023 Power 50: Movement Makers list is ranked number 33 on Boston Magazine’s 2023 list of The 150 Most Influential Bostonians, a 2022 recipient of the Cambridge Chamber of Commerce Inspire Award recognizing outstanding women leaders in the Cambridge community, a 2022 Boston power player as named by Axios, a 2021 executive fellow in the inaugural class of the Civic Action Project Collaborative, and a 2019 Boston Business Journal 40 under 40 honoree which acknowledges a leader’s impact on Massachusetts’ industries.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

Founder of the Center for Breakthrough Medicines - now part of SK Pharmteco.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Audrey, covering:

• How a career in real estate financial services led her to the world of cell & gene therapy
• The story of the creation of the Center for Breakthrough Medicines to its eventual sale and ‘fit’ with SK Pharmteco
• Why Philadelphia’s 'Cellicon Valley' is becoming one of the hottest life science clusters in the US
• Timeless tips on fundraising, networking and having a go for young people
• Her view on the market outlook for 2024 and beyond

Audrey is a serial entrepreneur, having founded three startups that have exceeded valuations above $1 billion. As Founder of the Center for Breakthrough Medicines, Audrey successfully launched the company, attracted 400 employees from around the globe, raised over $500 million in capital, closed a 15-year $100 million joint venture with the University of Pennsylvania’s Gene Therapy Program, and sold the company to SK Pharmteco.

Before launching CBM, Audrey founded Discovery Labs, which grew into the largest privately held life science real estate portfolio in the United States. She spent two decades as an executive in private equity, increasing assets under management to over $100 billion.

Awards have included being selected as the Top Trailblazer in Biotech, Most Influential Philadelphian, Titan 100 (2x), Healthcare Innovation Leader, and Woman of Influence. She is a renowned keynote speaker specializing in Cell and Gene Therapy, DEI initiatives, 'Cellicon Valley', and building bio innovation hubs.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Denise Bowser, Co-Founder and Commercial Director of Onyx Scientific.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denise, covering:

• The founding story of Onyx and helping the company gain traction in the early years
• A lesson in M&A - being acquired as a great business and being allowed to thrive as a great business
• The non-secret, simple secret sauce of retaining and growing clients over 20 years
• Functioning as a founder while feeling the force of Menopause... and timely advice for others in the workplace
• Advice for dealing with the downturn - diversification, doubling down on your core competence and customer care

Having founded Onyx Scientific in 2000, Denise has grown the business into a multi-million dollar CDMO with over 100 employees supporting clients in delivering their clinical programs in the pharmaceutical sector. With over 25 years of experience working with clients globally, Denise has built a successful business built on relationships & trust.

Denise plays golf in her spare time with a handicap of 16 & is an active member of her club, playing competitively for the team & loves getting out to nature, more recently discovering cold dipping & going on road trips in her campervan.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dominic (Nick) Marasco, Executive President and Chief Commercial Officer at Envision Pharma Group.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering:

• Building businesses, learning lots, and selling BioAgilytix
• With many options on the table... what was it that attracted him to Envision Pharma Group
• The real-life benefits and tangible impact of AI for pharma and biopharma companies
• Why great science and outstanding services that help will continuously be funded, irrespective of the ebbs and flows of the market

Dominic (Nick) Marasco is an entrepreneurial executive. He has over 25 years of executive experience in C-suite strategic planning, commercial operations, global business development, clinical Phase III trial design strategy, alliance management, financial resourcing, and P&L oversight within the Pharmaceutical, Biotech, and Medical Device industries.

Before joining Envision Pharma Group as Executive President and Chief Commercial Officer, Dominic served as Chief Commercial Officer of BioAgilytix, and in his tenure, he was actively involved in two buyer-side acquisitions and three integrations, as well as a seller-side sale of the company to new private equity owners, all within a 24-month timeframe. Before BioAgilytix, he served as Executive Vice President of Global Business Development and Commercial at Syneos Health, where he led the overall strategic direction of the worldwide business development team for the commercial division both in the U.S. and internationally.

He was previously Head of U.S. Sales for the Neuroscience Business Unit at Amgen, Inc., and before that, Global Commercial Head of Amgen Biosimilars. Dominic has also held commercial positions at Sandoz Biopharmaceuticals (a Novartis company).

He received his Bachelor of Science in Pharmacy from the Philadelphia College of Pharmacy and Science and ais an alum of the Harvard Business School Advanced Management Program. Dominic resides in Nevada.

Connect on LinkedIn: here

----

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Himanshu Gadgil, CEO at Enzene Biosciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Himanshu, covering:

• How a personal tragedy led him from the US to India on a mission to make an impact
• Shifting from a technical to commercial focus to launch several biosimilars in India and beyond
• Being at the inception of a big pharma biotech spin-out focused on building a platform of innovation that contributes to society
• Taking its cost-effective, continuous manufacturing platform from India to the US via a CDMO vertical focused on novel biologics

Dr. Himanshu Gadgil serves as the CEO at Enzene Biosciences Ltd. Under his services, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company. Prior to Enzene, he worked as the Sr. Vice President at Intas Pharmaceutical Ltd. where he was instrumental in turning around the commercial product pipeline by launching several biosimilar products in multiple geographies.

During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA, and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation, where he pioneered the development of QBD, enabling multi-attribute methodologies for biopharmaceutical characterization. Himanshu holds a Ph.D. in Biochemistry from the University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special end-of-year episode, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the 50+ episodes and special guest interviews throughout 2023.

In the second part of our series on the top trends 2023, we dive deep into the dynamic and ever-evolving life sciences sector. From its various life cycles to the winds of change shaping the industry in 2024, there is a positive upturn on the horizon.

In part two of the top trends from 2023, Raman identified trends including:

• How the M&A market has suffered in a fractured CDMO space over the last 12 months
• The new breed of biotechs coming to the life sciences market and what they are doing differently to be slimmer and more capital-efficient
• The rise of artificial intelligence and the importance it will play in the digitization of the sector 
• Why adaptability and flexibility are causing a sizable impact on an uncertain financial market in the life sciences sector
• Why the term “Green Shoots” is back in the life sciences vocabulary 

Catch up on Part One! 

Subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason Field, President & CEO of Lifesciences Ontario.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering:

• How the combination of his scientific background and his passion for public policy made him a perfect fit for Lifesciences Ontario (LSO)
• How the pandemic acted as a wake-up call and catalyst to kickstarting a coordinated industrial investment strategy across Canada
• The unique ecosystem of Ontario and Toronto, with its blend of plentiful STEM graduates and a thriving start-up and innovation community
• Why Ontario has gone from ‘flying under the radar’ to becoming a powerhouse cluster in the North American biomanufacturing and advanced therapies space

Dr. Jason Field is the President and CEO of Life Sciences Ontario (LSO). LSO collaborates with governments, academia, industry and other life science organizations across Canada to promote and encourage commercial success throughout the diverse sector.

Jason obtained his PhD in Chemistry from the University of Massachusetts and his B.Sc from the University of Waterloo. Jason’s professional experience includes the pharmaceutical industry and the Ontario government before joining LSO as Executive Director in October 2011.

He was appointed president and CEO in April 2014. He serves on several boards and advisory committees, including UofT’s Translational Research Program, ReMAP, BioTalent Canada, and Research Canada, and co-chairs the Resilient Healthcare Coalition. Jason is the 2017 recipient of the Distinguished Alumni Award from the University of Waterloo and Chair of Ontario’s Life Sciences Council.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Diana Kraskouskaya, co-founder and CEO of Dalriada

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Diana, covering:

• Exactly what ‘the Toronto paradox’ is...
• How two, seed-funded failures, led to identifying a gap in the market along with access to a rich talent pool
• The challenges and realities of starting, growing and scaling a CRO business to over 100 people
• Advice for other females looking to forge an entrepreneurial career in the drug development space

Diana brings years of leadership and hands-on cross-disciplinary biotech and drug discovery experience spanning areas of company building, scientific & IP program strategy, and operations.

She completed an Honors BSc Degree in Molecular Biology and PhD in Medicinal Chemistry from the University of Toronto and is a co-founder of two other biotechs, which have raised > $10 M in VC funding. Diana is the recipient of several entrepreneurship awards, including the RBC Prize for Innovation & Entrepreneurship and the 2018 MNP Future Leaders Awards.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special end-of-year episode, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the 50+ episodes and special guest interviews throughout 2023.

This special episode covers five key trends Raman identified including:

• The biotech slowdown in 2023 and how it affected the biotech sponsor space 
• Covid rebalancing and the macro-factors that have affected the sector 
• A continued focus on the life sciences supply chain - bringing supply chains closer to home
• A continued explosion of novel modalities, including Cell and Gene therapies, mRNA, and so on… 
• The importance of partnerships within the life sciences life cycle going forward… 

The life sciences industry has experienced a year of turbulence, as is often the case in this rapidly evolving sector. However, amidst the challenges, there have been positive changes taking place, and we are optimistic about the prospects for a positive 2024.

The dynamic nature of the life sciences industry ensures that things are constantly changing. Discoveries, advancements in technology, and evolving market trends shape the landscape and drive innovation. Despite the uncertainties and obstacles faced, the industry continues to adapt and thrive.

Part two of the series is coming to your favorite streaming platform very soon, so stay tuned for updates on where to find it and in the meantime, enjoy part one. 

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeffrey P. Kiplinger, Partner at Selling Science.

Your host, Raman Sehgal, sits down with Jeff to discuss his new book, 'Expert to Entrepreneur'. 

Jeff Kiplinger is a PhD chemist who, after leaving a scientific leadership role at Pfizer in 1998, transitioned to business leadership and an entrepreneurial track. In 2007 he founded Averica Discovery, an analytical drug development CDMO in the Boston area. With solid growth in a tough economy, Averica was an attractive target and was acquired by a Canadian lab services company.

Jeff left in 2018 and wrote about the experience of changing focus from science to business in his new book, “Expert to Entrepreneur: How to Turn Your Hard-Won Expertise into a Thriving Business”, which made the Amazon Bestseller list in its first week.

Jeff is passionate about helping scientist entrepreneurs build their businesses. He’s a keynote speaker and coach, leads mastermind groups for scientific founders, and is a co-creator and partner in Selling Science, a consulting firm that helps companies grow their revenue by developing successful sales programs. He still lives in the New England area with his wife Katy, and spends most of his free time outdoors hiking and cycling.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Clement Fourny, SVP of Commercial at SmartLabs.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Clement, covering:

• His journey of exploring options and opportunities, which led him to the life sciences space at just the right time
• Why modular labs and manufacturing suites as a service could provide a de-risked and cost-effective solution to those looking to conserve cash
• How the SmartLabs turnkey offering enables scientists to focus on the science and not infrastructure
• The value of building a collaborative ecosystem and community to harness more innovation

Clement has a 12-year diverse experience in the Healthcare / Life Sciences industry. Before joining SmartLabs, Clement spent his career at GE and Danaher where he built a track record of strong achievements and execution in sales, commercial operations and operational finance, mobilizing high-performing cross-functional teams to deliver sustainable growth and drive company goals.

In his prior role at Cytiva (previously known as GE Life Sciences), Clement was responsible for strategically supporting the global commercial organization of 3,000 associates with best-in-class sales operations services.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

Manuel Leal, Corporate Marketing Director at Ardena.

Eden Turner, Senior Conference Producer at Informa Connect Life Sciences

Catherine Hunter, Senior Commercial Manager at ramarketing

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology outsourcing events space, covering:

• How industry events are experiencing record numbers in a post-pandemic world
• The role of technology in making the most of trade events
• Calculating the real ROI when it comes to the biggest bucket in your annual marketing/BD budget
• Thoughts around sustainability and climate impact when it comes to a global event schedule

Manuel Leal is the Corporate Marketing Director at Ardena, a fully integrated Contract Development and Manufacturing Organization (CDMO) dedicated to advancing new molecules through clinical development. With over two decades of cross-industry experience, he has a unique blend of expertise in pharmaceutical business development and marketing. Manuel has more than 10 years of experience as a Business Development Director within the pharmaceutical CDMO industry. His contributions were instrumental in the growth of Idifarma, an organization that later became part of Ardena.

Eden Turner received her BSc. In Biological Sciences from Imperial College London. She went on to join Informa as a Conference Producer for two years and now has moved to Senior Conference Producer for three years working on Informa Connect’s Life Science Bioprocessing Portfolio, which expands events across the globe. Main areas of interest include Cell Line Development; Engineering, Upstream; Cell Culture, Manufacturing Strategy; and Bioprocessing 4.0. She is responsible for content creation and assists in market outreach.

Catherine Hunter is a Senior Commercial Manager at ramarketing and has over a decade of experience in the CRO and CDMO space across large and small molecule. With capabilities in a broad range of commercial disciplines, Catherine supports business development, project management, and events coordination for ramarketing. Passionate about helping companies to achieve their full potential, Catherine uses her business acumen to help ambitious companies fuel growth.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Bittorf, Founder and Principal Consultant of SCxCMC.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kevin, covering:

• Joining a little company called Vertex Pharma when it was looking to be innovative
• The leap of faith required to become a consultant, and why helping smaller businesses makes a bigger difference
• An insight into the sentiment of virtual, small, and emerging biotechs after a brutal 12 months
• What the most significant factor is in CDMO selection for biotechs, as well as other critical components
• Why CMC is a crucial investment from pre-IND to phase 2 to get things done on time

Kevin is an experienced consultant who has demonstrated success in pharmaceutical development (innovator and generics) and technical innovation. Leveraging his extensive experience in GMP, business development, contract manufacturing, and long-term strategy, Kevin partners with biopharma CEOs and executives to guide their companies through groundbreaking pharmaceutical advancements by evaluating strategy, attaining government approvals, and developing new and emerging technologies that improve the development lifecycle.

He has formed multiple non-profit conferences, including the Advancing Drug Development Forum, which examines how innovations are brought from inception to regulatory approval. He has spent time at Vertex and Trek Therapeutics and advising several CDMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Andi White, Head of Business Operations & Strategy for the Healthcare Industry Solutions Accelerator at Microsoft.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andi, covering:

• How five years at GE helped develop and shape Andi into a leader
• Why having a broad mindset early on in your career will help you flourish down the line
• The role of tech in revolutionizing clinical trials and drug development space
• How you should be thinking about and experimenting with AI in terms of data, convenience, and research

A clinically-savvy Ph.D. with two decades of diverse healthcare experience, Andi White has demonstrated success across all aspects of commercialization, in both start-up and Fortune 100 companies.

Andi’s corporate experience is bolstered by her years in the San Francisco start-up community, where she participated in the commercialization of several life science companies.

With a Master’s/Doctorate in Biochemistry from the University of New Hampshire and Postdoctoral research experience at UC Berkeley, Andi has a true passion for the science behind healthcare and the promise of connected data in driving the future of better patient outcomes.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

** Disclaimer **

The opinions, beliefs, and viewpoints expressed by Dr. Andrea White on this episode of the Molecule to Market podcast are solely her own and do not reflect the opinions, beliefs, and official policies of Microsoft Corporation.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Charles Ruban, CEO at Verdot.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Charles, covering:

• Crossing the border from supply chain to R&D, lessons learned from a technician turned business leader
• Creating the most extensive peanut allergy clinical trial in the world and opting for an IPO instead of a big pharma licensing deal
• How a call from a PE firm led to a spectacular exit
• Designing and creating downstream bioprocessing equipment in a Patagonia-inspired way - intelligent, sustainable, and functional - is critical for the future
• Why you need to know several biopharma trends, including AI, China R&D, and the fastest-growing therapeutic segment... you need to know

Over the last 25 years, Charles has held rich and diverse executive leadership positions in fast-growing international healthcare companies. His experience includes Manufacturing, Research and development, Business development, and Global Management in biotechnology and biopharmaceutical companies.

Charles is the CEO of VERDOT, a key player in bioprocessing, serving advanced solutions to the biotechnology and biopharmaceutical industry worldwide. Before this, he was the co-CEO at HTL Biotechnology, COO of DBV Technologies, and also spent considerable time at Eurogroup Consulting and Stallergenes.

He has been instrumental in streamlining supply chain operations, establishing strategic alliances, developing and launching therapeutic biologics in Europe, the United States, and Japan, and performing business activities. He has been heavily exposed to investors in both public and private environments.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dirk Lange, Head of Life Science Services at MilliporeSigma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dirk, covering:

• What he has learned from 25 years of bouncing around geographically in terms of cultural differences in understanding clients and colleagues
• Life on both sides of the fence as a drug sponsor and a CDMO, including key dynamics a buyer has to consider
• How MilliporeSigma has focused on ‘nesting’ its testing services, leading to the use of ’CTDMO'
• Insights into future trends including the need to deal with novel modalities in an agile way and digitally transform where possible

Dirk Lange is the Head of Life Science Services at the Life Science business of Merck KGaA, Darmstadt, Germany where he oversees the fully integrated Contract Testing, Development, and Manufacturing Organization (CTDMO) and Contract Testing services for the Life Science business.

He has over two decades of experience in life science client services organizations and an extensive background in clinical and commercial operations. He has held leadership roles at companies such as KBI Biopharma, Selexis SA, Novartis Biologics, Sandoz Oncology Injectables, and Rentschler Biopharma.

Lange received his Master Professional (CCI) of Technical Management and his Bachelor Professional (CCI) of Pharmaceutical Technology. He also taught Economics and Operations Management at the Chamber of Commerce and Industry in Ulm, Germany.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Fredrik Lehmann, Venture Partner at Industrifonden.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Fredrik, covering:

• How the closing of a business and customer requests led to a phoenix from the flames start-up opportunity
• His company's journey from inception and growth to eventual sale to Recipharm
• His transition to becoming a VC investor with an evergreen fund within the Nordic life science ecosystem, including the subjectivity of most investments
• The sentiment Fredrik is seeing from the biotech market and his frustrations of not being able to make more investments in breakthrough science and tech

Fredrik focuses on life science with an extra eye for innovative biotechs. He is interested in contributing to businesses with his experience in the biotech world to help companies reach their highest potential.

Fredrik has over 20 years of experience in the life science industry as CEO, Head of Research, and CMC in several companies. He has extensive experience in turning ideas into products and successful businesses and has founded six companies, including OnTarget Chemistry, which was acquired by Recipharm in 2015. He also serves as a board director at several Life Sciences companies and is a member of the Scientific Advisory Board at Akthelia Pharmaceuticals.

Fredrik holds a PhD in medicinal chemistry from Gothenburg University and an MBA from Stockholm School of Economics.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Belden, President of Tjoapack US.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering: 

• How the success of a contract packaging operation led to a divestiture from AmerisourceBergen to PCI
• The fun, games, and complexities of multi-national, M&A integrations
• Smaller patient populations and personalized medicines drive demand for more flexible and agile contract packaging providers
• Active listening, removing headaches from clients, and eliminating roadblocks are key to success

Peter is a leader in pharmaceutical services and is passionate about building teams that delight clients. He recently joined the Tjoapack team as President of, US, to help embark on the next stage of the company’s growth by delivering quality, service, and flexible solutions to clients.

With 25 years of service to pharmaceutical and biotech clients across packaging materials, contract packaging for clinical supplies and commercial medicines, specialty third-party logistics, and related commercialization offerings.

He has held leadership roles at AmerisourceBergen, Avery Dennison, PCI, and Clinigen Group.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, tune in for a special announcement about where to find Molecule to Market host, Raman Sehgal, at CPHI Barcelona this month.

Listen to the short episode covering:

• CDMO outlook - the trends and developments Raman expects to see this year and into 2024
• A fireside chat with Moderna covering COVID-19 and Oncology
• Panel moderation on the topic - Why building a collaborative network is essential

Are you heading to CPHI this month? Stop by one of Raman’s panels to gain valuable insights from leaders in the life sciences space.  Find the schedule in your CPHI app.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bruce Thompson, CEO of Kincell Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bruce, covering:

• The daunting and exciting prospect of launching a CDMO spin-out focused on early-phase companies
• The challenges and opportunities of pivoting a facility from innovator-owned to CDMO-owned
• Navigating from technical leader to a first CEO role... and the importance of covering your blind spots
• Why Bruce is seeing an upturn in the market and the emergence of more diverse opportunities.

Bruce is the CEO of Kincell Bio, bringing over 28 years of experience to his position. Before this, he was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped build the development and GMP manufacturing capabilities and served as a technical advisor internally and externally.

He has over 18 years of CMC strategy, product development, and cell therapy manufacturing experience. In his first startup role, he was Vice President of Process Sciences at Lyell Immunopharma, where he was responsible for Process and Analytical Development and tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Prior to Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He was responsible for supporting >15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs.

Bruce also spent nearly ten years at Pfizer in the Pharmaceutical Sciences division, and he received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University, and a Ph.D. in Microbiology and Immunology from the University of Louisville.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gordon Nicholson, Director of the Life Sciences NEA at Exyte.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gordon, covering:

• Transitioning from a regular, technical role into a commercial lead in Asia
• Lessons from sport and going back to basics when breaking down silos at Novo Nordisk Engineering
• Tips for building a presence and doing business in Asia from half a lifetime spent living and working in Thailand, China, and Singapore
• Being at the cutting edge of designing and building modern facilities for biologics, CGTs, and advanced therapies - including the rapid and complex needs of CDMOs
• A glimpse into the future of how CGT products may be made and administered at speed (safely) in the hospital in the next room from the patient

Gordon has more than 30 years of experience in designing and constructing Life Science facilities, from research to commercial production. He has worked on projects in Asia and the US for local and global pharmaceutical and biotechnology customers.

His responsibilities include leading the Life Science Concept Design Team in the Asia Pacific region, supporting clients through Business Development through the Technical review of documents before they are issued to clients.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Matthew Stober, Chief Executive Officer at Abzena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering:

• How the failure of a big pharma R&D portfolio led to the creation of a CDMO business and a pipeline-ready facility
• Leadership lessons for transitioning from a functional leader to an enterprise-level one, and being part of a board
• How failures at retirement and the desire to make a difference in the fight against cancer brought Matt back to the CDMO space
• A global harmonization move, and a legislative change this industry veteran believes our sector needs

Matt joined Abzena from his role at Istari Oncology where he served as President and Chief Executive Officer for two years. He has over 30 years of experience at large, multinational pharmaceutical organizations, in manufacturing operational roles.

Matt has previously held senior executive positions at Novartis Vaccines, Smith and Nephew and Hospira where he served as Global Head of Operations, President of Operations, and Senior Vice President of Operations respectively.

His deep and extensive operational experience has been consolidated from positions at companies including GlaxoSmithKline, Merck and Pfizer. Matt holds various Board positions including current appointments at X-Vax Technology, Istari Oncology and Castlevax. He holds a B.S. in chemical engineering from Villanova University, PA, USA.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with J.D. Mowery, President and Chief Executive Officer at KBI Biopharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with J.D., covering:

• The experience of bringing a product to market... and then many years later seeing that product used on his wife to help bring his sons into the world
• How bringing a commercial facility online for Genentech to impact thousands of patients compares to the ‘vain to vain’, hospital-based, one-off patient CAR-T product for Juno
• Why the ethos of taking care of the person on your left and the person on your right helps with the scale-up of a multi-national global CDMO
• The emergence of a partnership-based, absorption business model between innovators and CDMOs in the wake of the shift in capital markets
• What the next generation CDMO will look like…

J.D. is an accomplished leader with a distinguished reputation in the biopharma industry and proven expertise in guiding global innovators and contract development and manufacturing organizations (CDMOs) for nearly 25 years.

Throughout his diverse career, J.D. has demonstrated strategic vision and the ability to drive all aspects of an organization, including operations, R&D, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. He is an expert in diverse modalities, including small molecules, biologics, and cell and gene therapy. J.D. has held executive leadership positions as 

Head of Operations at Lonza and Executive Vice President of U.S. Operations at AGC Biologics. He has also held influential roles at innovators, including Genentech, Celgene, and Juno, and most recently served as Chief Operating Officer at Treadwell Therapeutics. J.D. holds a Bachelor of Science from George Fox University and an MBA from Marylhurst University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with TJ Higley, CEO at Microsize.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with TJ, covering:

• The fast, easy, scalable, precise, and non-patent-protected benefits of micronization
• How a synergistic capability alliance led to the eventual sale of his business to Lonza Capsugel
• The risks and realities of being an entrepreneur acquiring an organization, and then the collective rewards by incentivizing a team
• How a ‘getting the band back together’ call led to TJ taking back the site he once sold to create Microsize
• The importance of strategic partnerships and recognizing that you can’t do everything yourself

TJ joined Microsize in 2022 as CEO to lead the company into the next growth phase. TJ brings 25 years of experience in the pharmaceutical market, most uniquely as a former owner and executive leader of Powdersize, Inc., the original and first CMO focused on pharmaceutical micronization in the US. TJ led both the business development efforts and oversaw the site quality team during his tenure, culminating in the acquisition of the company by Capsugel in 2015 and the integration into Lonza in 2017.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Howard Berman, CEO and Chairman of the Board at Coya Therapeutics

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Howard, covering:

• How a neurology appointment with his father led to the creation of a biotech company focused on neurodegenerative, autoimmune, and metabolic diseases
• Having the DNA of an entrepreneur but taking the time to gain a big pharma foundation
• The harsh realities and characteristics required to start, fund, and grow a clinical-stage biotechnology company
• The need as a biotech CEO to be bullish, have confidence in your partners and be passionate about your disease... while celebrating the little successes
• Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel. He merged the company with Coya Therapeutics in 2021, where he currently serves as Chairman and CEO

He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines.

Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie. He spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for the development and initiation of collaborations, clinical trials and investigator-initiated trials.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Pamela Bush, Chief Business Officer at Predictive Oncology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pam, covering:

• The key aspects to successful deal-making learned over a decade with Eli Lily
• How a passion for curing cancer led Pamela to an opportunity to impact thousands of promising candidates directly
• How active machine learning is being used to screen molecules, help companies fail fast, and increase the success of a molecule in clinical trials
• The challenge of selling a disruptive, game-changing platform that could become a vital decision tool in the future

Pamela Bush, Ph.D. has over twenty years of experience in venture creation, finance, and business development in the life sciences industry. Pamela is the Chief Business Officer for Predictive Oncology where she leads the strategy and business development activities across the portfolio. Prior to joining Predictive Oncology, Pamela worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. In addition to her Lilly work experience, Pamela has worked in economic development, academia, and business consulting supporting the creation and growth of 100+ life sciences start-ups. Pamela holds a Ph.D. in Molecular Genetics and an MBA from Carnegie Mellon University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tushar Misra, Chief Manufacturing Officer at Mersana Therapeutics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tushar covering:

• How his opportunistic nature led him to several roles, companies and locations across the processing and biopharmaceutical sector
• Being given the task of building a worldwide manufacturing and supply chain infrastructure for the commercial launch of a biologic oncology product globally for Takeda
• Key components of a strong CDMO partnership ‘beyond checking boxes’ and how the type of product impacts the selection process
• The harsh realities of a recent clinical failure for a biopharmaceutical company that impacts employees and patients
• How the explosion of modalities have driven growth across all segments the outsourcing space

Tushar Misra is the Chief Manufacturing Officer at Mersana Therapeutics, a biopharmaceutical company specializing in the discovery and development a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. He has over 30 years of experience in developing drugs that involve small and large molecules and ADCs, as well as the development and management of worldwide commercial supply chains.

Prior to Mersana, Tushar was EVP, Head of Technical Development & Manufacturing at Laronde, where he led the process development and manufacturing team for end-to-end manufacturing for RNA products. In addition, Tushar worked at Takeda Pharmaceuticals in several positions of increasing seniority, most recently as VP & Head, Global Oncology and Biologics Operations.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mike Martin, Chief Executive Officer at CAI.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering:

• How a passion for engineering led to a lifetime in life sciences - including 32 years with Eli Lilly
• Why working in China, Puerto Rico, and Ireland and the exposure to new cultures changed this ‘mid-west farm boy’s view of the world
• A very short attempt at retirement... and what tempted Mike back into the working world
• Lessons learned from years of being the client, but also knowing when to dial down the client voice as a service provider

As the CEO of CAI, Mike Martin guides a team of 800+ across the US, Europe, and APAC for the global professional services firm focused on engineering and quality consulting.

With over 30 years in the pharmaceutical industry, including decades at Eli Lilly, Mike has experience in engineering, operational leadership, engineering leadership, and large-scale project management in diverse global settings, specifically major capital projects in the US, Puerto Rico, China, and Ireland.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kathy Fernando, Senior Vice President and Global Head of Pfizer Ignite and Pfizer CentreOne.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kathy, covering:

• How the forgotten step-child that is mRNA rose to the top of the technology vaccine tree
• Some of the key ingredients of the secret sauce that has dramatically improved the success of Pfizer’s R&D engine
• How Pfizer Ignite is positioned to assist capital-constrained biotech innovators, side-by-side, in several ways
• The intentional, sacrifice and discipline required to have a good balance of career success and healthy home life
• And what it’s like working with Albert Bourla, Chief Executive Officer at Pfizer

Kathy is a Senior Vice President and Global Head of the Pfizer Ignite Organization, and the Global Head of Pfizer CentreOne, within the Business Innovation Office at Pfizer. Her prior roles at Pfizer include Head of Worldwide Research, Development & Medical Operations and Head of mRNA scientific strategy. She also led efforts to develop an ambitious and holistic scientific strategy for mRNA across therapeutic areas as well as a well-orchestrated plan for execution.

Prior to joining Pfizer, she worked at Deloitte, helping address diverse business needs for pharmaceutical and biotech companies in the US and EU. Kathy has a Ph.D. in Immunology from the University of Pennsylvania. Her Ph.D. thesis focused on mRNA vaccine and HIV vaccine development. She has a bachelor’s degree in biotechnology from the Indian Institute of Technology (I.I.T) in Kharagpur, India.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tim Scott, President and CEO, AustinPx.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tim, covering: 

• The founding story of Pharmatek, and how client centricity and ‘training the hell out of the team’ contributed to the growth
• How the niche of being a spray drying expert led to a sale of Pharmatek to Catalent... and why he didn’t last very long post-acquisition
• The disruptive technology and team that got Tim so excited... he came back to the ‘CDMO+’ world in Austin
• Building traction for a game-changing technology for poorly soluble compounds to get it into 100 molecules and commercial products

Tim brings more than twenty years of pharmaceutical contract development and manufacturing organization (CDMO) leadership experience. Previously, Mr. Scott was co-founder and president of Pharmatek Laboratories, a CDMO where he led the growth and ultimate sale of the company to Catalent. He currently serves on the boards of multiple organizations, including Avelas Biosciences, DTx Pharma, CONNECT, BIOCOM, and the University of California, San Diego’s Dean’s Advisory Council for the Division of Biological Sciences. He previously served on the board of Zacharon Pharmaceuticals (sold to BioMarin in 2014). At UC San Diego, Tim has founded or supported multiple biotech spinouts including Zacharon, TEGA therapeutics, LipoNexus, Knoubis Bio, Nerio and Augment Biosciences. Mr Scott earned his BA in Biochemistry from UC San Diego and his JD from the University of San Diego. He is a member of the California Bar.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Graham Wylie, Executive Chairman at the Medical Research Network (MRN).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Graham, covering:

• Transitioning from Pfizer’s in-house R&D team to a senior commercial BD role at Parexel
• The brutal experience of leading an MBO deal and why you should go into any deal with ‘your eyes open'
• How the fast-paced CRO world has evolved over the last 20 years, and what the future may hold for the clinical trials space
• How Graham built an entrepreneurial, family business with a view on the long term plan that includes his wife and kids
• How being used to fast growth as a specialist CRO better prepared MRN for the impact of C19 and 90% growth

Dr Graham Wylie graduated in pharmacology in 1982 and then in medicine in 1987. He moved into the Pharma industry in 1989, spending 10 years at Pfizer and 5 years at Parexel in many different forms of clinical trial management before joining Healthcare at Home to create a trials division. He led an MBO to make this a separate company in 2006 and was CEO and majority owner for 16 years, until September 2022, when he passed over the CEO role to one of his (younger) co-founders, and became Executive Chairman. Through that period MRN enjoyed an average growth rate of 35% through feast and famine and continues to be one of the fastest-growing founder-led businesses in the UK.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• James Edgar, Chief People Officer at Sygnature Discovery
• Andrew Mears, CEO and Co-founder at Lead Candidate
• Laura Child, Head of Research and Strategy at ramarketing

Your host, Raman Sehgal, discusses pharmaceutical and biotechnology talent challenges and solutions with his guests, covering:

• Where the industry-wide talent challenge originates, and practical solutions of how companies can take steps to overcome it
• The role of a talent attraction team, a recruitment expert, and your employer brand in getting ahead of the curve when it comes to building a people pipeline
• Mapping and flawlessly executing your employee experience value proposition when attracting, onboarding and engaging your stars
• Staff retention challenges across the board and when things go wrong with your people

James Edgar has been in post for 12 months and has joined to support the growth of the company into its next phase with the development of Sygnature’s Employee Value Proposition. He has over 20 years in the People and Human Resources field. He comes with multi-sector experience from Financial Services, Manufacturing, Facilities Management and more recently from Advertising and Media sector with WPP.

Andrew Mears is CEO and Co-founder of Lead Candidate, a specialist talent acquisition consultancy exclusively supporting the global pharma and bio-outsourcing sector. He has more than two decades of experience working in human resources and talent, developing and delivering talent initiatives to help fast-growing companies achieve ambitious change and growth agendas.

Having built an impressive career as Program Director in some of the largest multinational CROs, delivering high-value and high-complexity global trials, from Ph 1 through Ph 3, Laura joined ramarketing as Head of Research and Strategy. In this role, Laura works closely with a team of senior marketers and Sector Specialists to conduct in-depth research projects to deliver data-driven brand and growth strategies for clients.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Founder and CEO at Vibe Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alok, covering:

• The personal story that motivated and inspired Alok to create a rare disease platform focused entirely on creating an ecosystem focused on high potential medicines.
• Lessons from ‘the grind’ of raising over $100m in capital, and why you need a ‘Minimal Viable Investor’ (MVI)
• The macro impact of Covid-19 in highlighting the importance of medicines - and why this is a time for optimism, innovation and technology in biotech.
• The catch-22 of inflection points for biotechs and how that impacts access to capital. And whether AI could play a pivotal role.
• How CDMOs and CROs need to evolve away from just the fee-for-service model to explore longer-term, partnership-led alternatives.

Alok has 15 years of experience as a scientist and 12 as a serial entrepreneur. After completing postdoctoral work at Harvard University with George Whitesides, Alok started two pharma SaaS companies, PreScouter and TetraScience, which employ several hundred people combined and have more than four hundred customers. He also launched and led the life sciences division of Egnyte, a cloud content governance company based in California, and grew the business to a 60-person team and eight-figure run rate.

Alok founded Vibe Bio after his daughter was hospitalized at birth and he learned first-hand that the biggest obstacle to developing treatments isn’t finding potential therapies — it’s funding them. Vibe Bio is helping patients in similar situations overcome that obstacle by scaling the development of treatments for rare disorders sustainably for the first time. He holds a B.S. from Cornell and a Ph.D. from Northwestern, both in Materials Science & Engineering.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special episode of Molecule to Market, instead of going inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, you'll hear a special announcement about the show moving to Toronto!

The announcement reveals why our show sponsor, ramarketing is opening a new office in Canada and what this means for your favorite podcast and host.

Listen to the short episode to hear:

• About the drivers behind ramarketing's decision to establish a second office in North America
• Why the agency selected Toronto, or T'rono as the locals say
• Discover what the move means for Raman and his family, in addition to the ramarketing team and future talent acquisition
• The benefits of locating to one of the most diverse cities in the world
• How ramarketing and Molecule to Market plan to tap into the thriving life science ecosystem and 'Pill Hill' located in the Greater Toronto Area (GTA)

The announcement is a real milestone for ramarketing as a business and for Molecule to Market.

The show hopes the move will provide access to even more incredible guests! Giving our host access to more people to outreach and hopefully attracting new people - listeners, followers and guests.

So, from late August onwards, you'll be hearing from Molecule to Market in a new location. We'll keep our loyal listeners informed of how the move is going and what life is like for Raman, his family and our team in Toronto.

Until then....take care. Thank you for listening!

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international mark

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Barbara Morgan, Global Vice-President of Pharma and Biotechnology at Kerry.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Barbara, covering:

• Believing in herself and being brave enough to leave a company that felt like family in a job that she loved
• Why Pharma has proved itself to be indispensable, while the biopharma slowdown is just a blip
• The difference between mentors and sponsors, and why you need a blend of both
• Lessons for mastering M&A assessment and integration for prioritizing impact

Barbara Morgan is Global Vice-President, Pharma, and Biotechnology at Kerry. Prior to that she worked at LLS Health (part of Lubrizol) from 2014 until 2021 and was named General Manager in 2018.

With a Ph.D. in Organic Chemistry from the University of Pennsylvania (US), Dr Morgan has more than 15 years of experience in the Life Science industry, covering pharmaceutical, nutraceutical, and medical devices.  She has published numerous articles in peer-reviewed journals and holds patents, including one on the treatment of cancer stem cells.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marcel Velterop, CEO and Member of the Board at Primopus.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcel, covering:

• Tips for technical people looking to transition and navigate into a commercial career path
• Why the CDMO business is not for the faint-hearted given the brutal focus on execution and results
• Insights from a lifetime of doing business in India and the key components of a successful tech transfer across multi-national sites
• How oligonucleotides have gone from niche to mainstream, and why an oligos platform presents a major new tool in the healthcare toolbox

Marcel holds a masters degree in chemical engineering from Delft University of Technology and started his career at DSM where he spent 14 years in various roles of growing responsibility. He then joined Dr Reddy’s Laboratories CPS, a CDMO, and subsequently worked for large Indian providers like Sai Life Sciences and Jubilant Biosys. He gained extensive international experience during his 4 years in the US and now over 15 years in Switzerland and aims to work with cultural differences globally and build productive collaborations.

He found purpose in the pharma industry and helping drive innovation as a service provider in the CDMO and CRO industries. During the Covid times, an opportunity presented itself to work for a large India CDMO, who had acquired a GMP API plant just outside Basel, Switzerland. As CEO of Primopus he is building a hybrid business model with complex RSMs and intermediates supplied out of the Swiss site with full backward integration from the large capacity available in India at its parent company.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jesse McCool, Co-Founder and CEO at Wheeler Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jesse, covering:

• His journey from the Lonza bench to the boardroom as CEO of Cytovance CEO before becoming a founder
• Building a CDMO from a blank canvas via a pit stop of C19 testing
• What makes Oklahoma City an attractive place to do business with its mixed blend of life science, tech and biomanufacturing expertise
• How Wheeler’s hub and spoke satellite business model and platform is changing the CDMO business model

Jesse McCool is the Co-Founder and CEO of Wheeler Bio, an agile, small-batch biologics drug substance manufacturer focused on addressing unmet needs in the translational space. He has over 20 years of biologics development and manufacturing experience in biotech and CDMO environments. He previously held executive and technical positions at Cytovance Biologics, Lonza, Lallemand/Mascoma, Dartmouth, and Clean Harbors.

He joined Cytovance Biologics in 2013 to build out and lead the process development organization. The company was acquired by Hepalink in 2015 after which he was named Director, Chief Technical Officer and eventually, Chief Executive Officer. Jesse left Hepalink following the successful HK IPO in 2020 ($500MM USD) to join OKC-based venture studio, Echo Investment Capital, as Entrepreneur-In-Residence. He co-founded and launched Wheeler Bio in 2021.

He also serves on the Governor’s Council for Workforce and Economic Development (State Commerce) and works on numerous workforce development initiatives in the biomanufacturing sector. Jesse earned a Ph.D. from the University of Massachusetts at Amherst and completed his postdoctoral work at Dartmouth (Hanover, NH) and Delft University of Technology (The Netherlands). In addition to his industry experience, Jesse is an established public speaker, researcher, and peer-reviewed journal author and contributor.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lung-I, covering:

• His take on the different models of healthcare he has seen globally, and the value they do and don’t deliver to patients
• The access, and infrastructural challenges of CGT products and ways to bring the cost of goods down
• Why CGT is the therapy of the future... but why we must remember it’s not the only modality out there
• What the future looks like for CGT and exploring what happens when we have a treatment that can treat a lot more patients

Lung-I Cheng, Ph.D., is Vice President, Cell and Gene Therapy, leading AmerisourceBergen’s Cell and Gene Therapy (CGT) service line. In his role, he advances AmerisourceBergen’s CGT strategy with a focus on expanding the company’s portfolio of services to better support CGT innovators throughout the commercialization journey.

Before joining AmerisourceBergen, he spent a decade in biopharma, most recently serving as the head of Global Value & Access for Cell Therapies, Pipeline, and Business Development at Takeda.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Shawn Singh, Chief Executive Officer and Director at Vistagen Therapeutics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Shawn, covering:

• What life is like running a public company and how that is impacted depending upon the season of the capital markets
• The ups, downs and pivots of a biopharmaceutical company that’s led it down a mission of transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders
• How the pandemic has magnified mental health issues and their prevalence among young people, and why finding a radically social transformative treatment is needed
• Why collaboration is key when developing several drug candidates and how partnerships can happen at any stage of the lifecycle
• His views on CROs, CDMOs, what is essential to outsource in the vendor universe... and the most critical asset to a biotech boss

Shawn is an experienced public company Chief Executive Officer and Director. He has over 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles.

He’s an attorney and a member of the California State Bar with a Juris Doctor from the University of Maryland Francis King Carey School of Law.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Wayne Woodard, CEO at Argonaut Manufacturing Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Wayne, covering:

• How a career in the famously outsourced semiconductor industry benefited his route into the outsourced life science space
• The basic thesis that led to the start-up of Argonaut and the deliberate intention to ‘skate to where the puck will be’
• Wayne’s aim (and achievement) of creating something special that would also help people and pay forward
• Key considerations and benefits of being located on the West Coast of the USA... including wine

With 35 years of management experience in operations, supply chain and general management, Wayne Woodard’s primary focus (in three different industries) has been on building global operations capabilities with particular emphasis on working with external manufacturing services companies.

Before founding Argonaut, Wayne most recently worked at Thermo Fisher/Life Technologies through its Ion Torrent acquisition. He previously worked at Affymetrix, Electroglas and Ridge Technologies. Wayne began his career in manufacturing at Sun Microsystems. Wayne focuses intensely on execution and detail, which is why he also bottles his own wine.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Richard Weaver, Founder and Managing Director at Drug Discovery Solutions.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:

• How his curiosity to learn at AZ led him to realizing he was an entrepreneur
• The opportunistic start-up story and impressive growth journey of XenoGesis up to the eventual, successful sale to Sygnature Discovery in 2020
• Lessons learned and milestone moments of a scientific entrepreneur
• Why biotechs are here to stay... outsourcing is here to stay... but why offshoring is not

Richard is Founder and Managing Director of Drug Discovery Solutions Limited. Previously CEO and founder of XenoGesis, he grew and led the successful sale of the business to Sygnature Discovery in 2020. Prior to that, he spent 14 years at AstraZeneca.

He is an expert of all aspects of R&D including Due Diligence of companies/assets. Specialist in Drug Metabolism & Pharmacokinetics (DMPK) from Hit Identification (HI) to Candidate Drug (CD) nomination and pre-clinical development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vishnu Dwadasi, Director of Manufacturing at Ashvattha Therapeutics Inc.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vishnu, covering:

• Lessons learned from 15 years in CDMOs and consulting, before joining a start-up drug development company
• What he’s learned from working with and managing CDMOs all over the world
• Why many CDMOs are behind the eight-ball... fancy marketing meets chaotic operations
• The challenge of scaling up through phases as a drug sponsor, and the evolving needs when it comes to outsourcing
• Major frustrations as a client in a post-covid world and the one area every CDMO needs to invest in moving forward

Vishnu Dwadasi is currently a Director of Manufacturing at a biopharmaceutical start-up company, Ashvattha Therapeutics, leading drug programs from pre-clinical to commercialization.

Vishnu brings over a decade of experience in life sciences with a unique background in pharmaceutical operations, consulting, and business development. He has developed extensive experience shepherding complex drug development programs from early clinical development to full-scale commercial manufacturing and distribution. Along with his drug development experience, Vishnu has gained expertise in operations and implementing technology solutions for life sciences companies.

Vishnu earned an MBA from Duke University and a B.S. in Health Sciences from Purdue University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Ross Burn, Chief Executive at CatSci
• James Hales, Senior Director at NorthEdge
• Tom Cowap, Managing Director for Pharma Services at Baird

Your host, Raman Sehgal, discusses pharmaceutical and biotechnology supply chain M&A activity with his guests, covering:

• How the market headwinds, continued consolidation and macro slowdowns are impacting M&A activity in our space... if at all...
• Why PE is still very keen on the pharma and biotech ecosystem and why the size and shape of deals and investments in the market have changed.
• How an investment is enabling Ross’ business to accelerate growth in several directions.
• A look forward to geographic shifts, continued biotech outsourcing, and how there maybe riches in the niches of sub-segments of the pharma services ecosystem.

After completing his PhD in 2007, Ross joined AstraZeneca as a Senior Analytical Chemist in process R&D. Ross’ analytical expertise and entrepreneurial mindset was pivotal to the establishment of CatSci Ltd in 2011. Ross became CEO in 2015 and has since led the company’s pivot from a catalyst screening company to the award-winning innovation partner for medicines development that it is today. As such, Ross was included on the 2021 edition of The Medicine Maker’s annual Power List of inspirational professionals in the pharmaceutical industry. CatSci received PE backing in 2022.

James is a Senior Director at NorthEdge and leads the healthcare origination efforts as part of the wider healthcare sector team. He is fortunate to meet with management teams nationally across a number of sub-sectors to understand their plans and to identify new investment opportunities for NorthEdge via growth and development capital, management buy-outs, equity release and buy-and-build opportunities. Prior to joining NorthEdge, James spent seven years in Corporate Finance at Clearwater International where he was a Director responsible for generating mid-market opportunities and managing the Deal Origination team.

Tom is a Managing Director in Baird’s European Healthcare Investment Banking team. Tom joined Baird from Alantra where he spent nine years building Alantra’s pharma services coverage effort, providing M&A services for financial sponsors and independently owned, founder backed businesses in the space. Prior to Alantra, Tom worked at PricewaterCoopers in their Financial Due Diligence team. He also served in the British Army (Reserve – 7th Battalion, The Rifles and 4th Battalion, The Yorkshire Regiment). Tom is an ACA and had a bachelor’s degree in finance from Durham University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Will Patrick, CEO at Culture Biosciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Will, covering:

• How time at Google, MIT and Kendall Square led him to build disruptive tools and hardware for the bioprocessing sector
• Creating a cloud-based, real-time data alternative for companies wanting access to bioreactors... without the need for large-scale investment
• Why biotech and biopharma firms are embracing digitization, virtualization, and simulation... but less so at CDMOs
• Raising funds from VCs that understand the need for technological disruption
• How biotechs, biopharma companies, and CDMOs alike can leverage Culture’s proprietary, integrated, and cloud-based single-use reactor platform
• How enhanced data-driven modeling and simulation can save a lot of time and costs in upstream bioprocess development going forward

Will is an entrepreneurial engineer with a background in mechanical engineering, product design, and bioengineering. He develops hardware products at the interface of biology and digital fabrication. He holds 17 patents and has published 4 peer-reviewed journal articles. He currently runs Culture Biosciences, a company building and operating automated bioreactor infrastructure for the biotech industry.

Will graduated from the MIT Media Lab in 2015 where he was a researcher in the Mediated Matter group. His research focuses on 3D printing fluidic systems and their applications in biotechnology and product design.

Previously, he worked at Google[x] as a Rapid Evaluator where he developed and prototyped new projects for the organization. Will was a founding member of the Google[x] UAV delivery project, Project Wing, was an early team member of Project Loon, and also led the launch communications for Project Glass.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with  Ian Walters, CEO and Chairman at Portage Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering:

• What Ian learned from his time working with a team of Nobel Prize winners at Rockefeller University
• Breaking the mold by launching a clinical trial in just three months versus the 12-month standard in a big pharma firm
• Why building relationships with big pharma is key as a small biotech company with multiple assets in the pipeline
• How his lean biotech is running the most rapid proof of concept studies in the market whilst conserving cash and building value
• Why manufacturing and reliance on CDMOs have been the biggest challenge to his business

Dr Ian Walters has over 20 years of leadership and expertise in oncology/immunology drug development and specializes in the evaluation, prioritization and innovation of new therapies for the treatment of severe diseases. 

Prior to Portage, Ian spent seven years at Bristol Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds and biomarker and companion diagnostic work. He was a core member of Bristol Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations and the company’s immuno-oncology strategy. Prior to BMS, he held positions at PDL BioPharma, Inc., Millennium Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs.

Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated advanced immunology research to understand the mechanism of action of several compounds. Ian received his M.D. from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, CFO, Special Advisor & Board Member of several biotech companies, including Portage Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:

• Allan’s updated view on what is happening in the market since he was on the show last summer and his own change in investment focus
• Why a downturn, negative enterprise value, and cash burn for many biopharma and biotech firms signals an opportunity for others
• A new breed of slimmer, capital-efficient biotechs that will have a reliance on outsourcing built into their de-risk strategy
• Why the capital-intensive CGT area is not always a sure thing - investment tips from someone that has helped raised more than $4 billion in funds

Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audits and two compensation committees.

He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing; an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Oren Beske, Amalgamator of Business and Biology at ATUM.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Oren, covering:

• How he ended up at Atum with one of the most peculiar job titles in the industry...
• The balance (and conflict) of combining a world-class science offering with the economic need of needing to monetise a business
• The journey from transactional, smaller deals in the pre-clinical space to powering outsourcing for biotechs
• The realities of drug development capability sharing in return for a slice of the profit pie, and its upsides when it comes to a CRO vendor and drug sponsor model

Dr. Oren Beske joined ATUM in 2019 and brings over 20 years of industry experience to the team. After receiving his Ph.D. in Cell Biology at UCSF, he led a biology team at an automated microscopy start-up that was developing solutions for the high throughput, high content screening industry. Having spent over five years there he moved from product development to the services industry and joined Aragen Bioscience. Whilst joining early in the building of the company as the director of laboratory services, he moved up through the VP level and into various C-Suite roles over nearly 11 years and led the company through the acquisition by GVK Bio.

Following a short stint as the president of ImmunoPrecise Antibodies, he most recently served as the founding CEO of Alloy Therapeutics, Inc. serving to set up the company, in-license its seminal discovery platform, and get the first customers on board.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Derek Hennecke, biotech and CDMO Entrepreneur and Board Member.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Derek, covering:

• The behind-the-scenes story of acquiring, growing and selling Xcelience to Capsugel
• Why Derek loves a carve-out with a clear differentiating capability and bags of growth potential
• How he thinks about investments in both a VC and PE capacity, and how this has evolved
• Why Derek is not seeing a slowdown across his portfolio companies…but why there could be a lag

Derek is a biotech entrepreneur and Chairman of various boards, including Microsize and Particle Dynamics. With over 30 years of experience in the CDMO industry and a 2022 Master’s degree from Harvard in the Inceptor Bio lab, he has developed a deep understanding of pharmaceutical development and manufacturing, and as a Partner at Kineticos Ventures, he invests in biotech companies that are pushing the boundaries of what’s possible in oncology through technologies like gene editing, mRNA, and CAR-T.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Anderson, General Partner at Ampersand Capital Partners.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• What a world-class healthcare PE company looks for, and is repelled by, in a pharma services acquisition target
• Behind the scenes of some of the biggest M&A deals in the outsourcing space in recent years - including Brammer Bio’s sale to Thermo
• Beyond the dollars of a deal - the importance of relationships, trust and straight talk
• What life is like on the board of several fast-growing advanced therapy companies
• Insights on key market tailwinds and where Ampersand plans to invest its $1.2bn fund

David joined Ampersand in 2010. Previously, David spent six years with Covington Associates, a specialty investment bank focused on middle-market M&A in the healthcare sector. Prior to Covington, he spent five years as a consultant for Boston Healthcare Associates. David’s board seats include Genezen, Arranta Bio, StageBio, Protogene, BioClinica, Brammer Bio, Cellero, and Vibalogics. David holds a B.Sc. from the University of Aberdeen, a Ph.D. in Immunology from the University of Sheffield, and an M.B.A. from Babson College.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Paul Dickinson, Founder and CSO at Seda Pharmaceutical Development Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Paul, covering:

• The success factors and a behind-the-scenes look at one of AstraZeneca’s fastest development programs – from the start of clinical trials to approval in just over two and a half years to meet unmet lung cancer needs
• How working with CROs and CDMOs led to identifying a poorly served niche between clinical development performance and rapid early-phase manufacturing
• Leaving AstraZeneca after years of success to bring collective expertise to a broader audience… “jumping in’ and proving they had what it takes
• The rollercoaster of starting and growing a business, the feeling of ‘good anxiety’, and why the value of a scientific mindset in running experiments has paid off in the business world

Paul has held several senior science leadership roles in Academia and Large Pharma. These roles focussed on applying the best science in projects to ensure optimal product performance in the patient, thus bridging pharmaceutical and clinical disciplines. He founded Seda Pharmaceutical Development Services, a company focused on delivering pharmaceutical development (CMC) and clinical pharmacology services to the Pharma industry.

Prior, Paul led AstraZeneca’s clinical pharmacology program to NDA/MAA for AZD9291, which was the highest priority project in the AZ development portfolio and had been awarded ‘breakthrough therapy’ status by the FDA. As a result of both his internal and external scientific leadership, he has been awarded numerous science and innovation awards by AstraZeneca. Paul has published >30 research papers, 5 patents, 2 book chapters, and presented numerous invited lectures and conference abstracts.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jennifer Chadwick, CSO of ProtaGene.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jennifer, covering:

• Lessons and learnings moving from the world of academia into commercial industry
• The shift from lowest-price tactical outsourcing to value-based, holistic, and strategic outsourcing at a much earlier stage
• Nuances in the sandbox of playing with the buckets of CGTPs, and why emerging therapeutics do not play by the rules
• The increasing importance of risk-based assessment in early-stage drug development, and the need to increase the bar for understanding complex modalities in a smart, cost-effective and efficient way as we begin to understand them more

Jennifer Chadwick is Chief Scientific Officer of ProtaGene and serves as Site Head in Boston. She brings two decades of experience leading scientific teams in the biotech industry and academia and is a well-recognized expert in development of biologics and gene therapy products.

She served as Vice President of Analytical Development and of Biologic Development at BioAnalytix. Previously, Dr. Chadwick was a tenured Professor of Pharmaceutical Chemistry at the University of Kansas.

Jen has authored thought leadership articles related to analytical development of gene therapy products and published approximately 75 peer-reviewed publications, 13 patents, and four book chapters, demonstrating her expertise and deep understanding of biologics and drug development.

Dr. Chadwick has served as an Associate Director of CASSS and a member of the Steering Committee for academic-industry relations at the Massachusetts Biotechnology Council. She is also a Visiting Scholar in the Department of Chemistry and Chemical Biology at Northeastern University. She received her PhD from Purdue University Department of Chemistry.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Henal Shah, Life Sciences Lab Practice Head at Cognizant.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Henal, with a focus on:

• Decoding digital transformation and what it means for pharmaceutical companies across the life sciences supply chain
• Delivering fascinating insights into what a state-of-the-art smart factory and lab of the future look like
• The complexity of collating siloed data and connecting, orchestrating and presenting it into meaningful information that aids improved decision-making
• The four key trends Henal is seeing driving the pharmaceutical laboratories sector right now

Henal is Head of the European Lab Centre of Excellence (CoE) Practice within the Life Sciences Manufacturing Group at Cognizant. Holding a management degree in marketing, she has more than 20 years of experience in multiple sectors, primarily in life sciences pharma.

Henal has led the Life Sciences Quality Engineering and Assurance practice for more than a decade within Cognizant across the UK and Ireland. Her experience spans through lab systems implementation, lab digital transformation, lab automation, mergers and acquisitions, GxP validation, and testing and compliance across the life sciences value chain including discovery, research and development, manufacturing pharmacovigilance, and sales & marketing to product launch.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Bamforth, Entrepreneur, Mentor and Investor in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:

• How an unsolicited offer led to the unplanned sale of Arranta Bio to global CDMO Recipharm
• Mark’s ability to spot trends of where the sector is going, and sometimes going against conventional wisdom
• How Mark thinks about investment in early stage and later stage companies, as an investor
• His take on the tougher, tighter funding environment and what it means for the market
• Leadership lesson from 20+ years at Genzyme and three founder-to-exit successes

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Bamforth, Entrepreneur, Mentor and Investor in life sciences.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering:

• Mark’s backstory from oil barrels to brewing, to a small biotech called... Genzyme
• A baptism of fire of having to raise money for a self-funded CDMO carve-out after 22 years in the corporate world
• How a merger strategy led to the sale of Gallus BioPharmaceuticals to Patheon
• Entering the viral vector space, and the story of Brammer Bio from start-up to a $1.7bn exit to Thermo

Mark founded, built, and sold three CDMOs over a period of 12 years. Gallus Biopharmaceuticals was focused on monoclonal antibodies, Brammer Bio produced viral vectors for gene therapy and Arranta Bio produced microbiome, plasmid and mRNA vaccines. In total, over 1,200 jobs were created and over 100 client clinical trial projects were enabled.

Prior to this, Mark previously spent 22 years at Genzyme, latterly running the 12-site global manufacturing operation and a pharmaceutical CMO business. He began his career as a petroleum engineer with Britoil, then as a chemical engineer with Whitbread.

He serves on the boards of Continuus Pharma, Pneumagen, Enterobiotix, Inceptor Bio, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal, covering his top tips for networking ahead of this year’s events season after two decades of learning the do's and dont's, and making the mistakes for you.

This episode covers;

• The importance of networking and how vital human interaction is to keep business going
• Being your own brand and understanding your network is your net worth
• Judging a book by its cover, and how that very thinking could cost you your next big deal
• Adding value without pushing for the hard sell
• How nurturing contacts and connections can reap rewards years down the line

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal for a special lookback episode on the topic of diversity in the life sciences space.

This week’s episode features excerpts from conversations with;

• Barbara Morgan (Lubrizol at time of recording), now Global Vice President, Pharma and Biotechnology at Kerry discussing; gender diversity and the network of women supporting each other in their roles.
• Tia Lyles-Williams, founder & CEO at LucasPye Bio discussing; the recent political climate and how that has affected steps forward in diversity and inclusion.
• Jeff Dill, CEO at Vynamic discussing; the importance of diversity at his organization, and what they have put in place to ensure EDI goals are being achieved.
• Andrew Moore, General Manager at Pfizer Center One discussing; his experience as a person of color in the sector, and how the conversation has changed in his time.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tom Ross, President and CEO at Grand River Aseptic Manufacturing (GRAM).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• How a passive investment in a small growing business led to running one of the most reputable CDMOs in the US
• Insights of how to pivot from lumpy clinical supply to sustainable commercial revenues
• The ups and downs, opportunities and challenges of growing a business at over 700pc+ as one of Inc Magazine’s fastest growing companies in the US
• Being on the inside of Operation Warp Speed (OWS) and what it took to gear up for global Covid vaccine supply
• Dealing with the Covid comedown and transitioning a 100% capacity utilization with new projects including the monkeypox vaccine

During his career, Tom has held senior executive roles at a large, publicly held pharmaceutical company and at leading, smaller entrepreneurial organizations. He spent eight years at Perrigo Company, a multi-billion-dollar generic and OTC pharmaceutical company, where he served on the executive committee and led the financial team. Tom left Perrigo to help set up the processes, systems and infrastructure for two smaller, high-growth companies. He also served as managing director at DWH, LLC, a consulting company focused on helping emerging businesses maximize value.

Tom, who joined GRAM in 2013, received his Bachelors in Accounting from Michigan State University and completed coursework for an MBA at the University of Miami. As President and Chief Executive Officer at GRAM, Tom Ross uses his extensive managerial and technical expertise to create a culture where employees can maximize their performance. A skilled communicator, Tom helps develop teams to create compliant processes and systems that deliver results to clients.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ian Tzeng, Managing Director at L.E.K. Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering:

• Insights, trends and advice for CROs, CDMOs and pharma services firms from one of the most prominent life science consultants.
• What he gained from his time studying at Harvard and the importance of genuine curiosity and a multi-disciplinary way of thinking.
• The complexity of modality and technology fragmentation, and the challenge of picking the right ones from a CDMO perspective.
• Why focusing on ‘conserved areas’ and ‘platform technologies’ could be a smart move when thinking about diversification and long term investments.
• The shift we are seeing from volume-based blockbuster drugs that deliver billions of pills to the masses, to targeted speciality drugs, to even more advanced therapies for micro-patient populations.

Based in the Boston, Ian has 20+ years of consulting experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He directs projects across the healthcare spectrum with particular emphasis on Biopharmaceuticals & Life Sciences and MedTech practices.

As a focus area, he leads L.E.K.’s pharmaceutical contract services practice. Additionally, Ian has extensive consulting and board experience with non-profit organizations in education, arts, LGBTQ+ advocacy, and public service. He received a Bachelor of Arts degree, magna cum laude, in Chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering:

• How a family ritual of solving puzzles played a role in developing an entrepreneurial spirit of problem solving
• Learn about how and why Northern Texas is becoming a destination for biotech and life sciences
• Going viral for being viral... and why covid was the time for immunologists to shine
• The opportunities and challenges of introducing innovative, disruptive technology into the biopharma space

Claire Aldridge, Ph.D. is Chief Strategy Officer for Form Bio, the first spinout from the de-extinction and biodiversity company, Colossal Biosciences. Prior to this role, she was Senior Vice President, Chief of Staff and Corporate Strategy at Taysha Gene Therapies, a Dallas based company focusing on eradicating monogenic CNS disease. She previously served as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center and VP, Venture Development with Remeditex Ventures, a local biotech venture fund.

Dr. Aldridge brings more than 20 years’ experience facilitating the translation of scientific discoveries into patient and commercial benefits. Dr. Aldridge is also on the Scientific Advisory Board for Colossal Biosciences, the Board of Directors for MedCognetics and 4E Therapeutics and is the chair for the Industry Advisory Council for the UT Dallas Department of Biomedical Engineering. Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Harry Christiaens, CEO at Ardena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Harry, covering:

• How a regulatory change led a small consultancy down the path of becoming one of Europe’s most respected mid-sized CDMOs
• The easy-theory of an M&A buy-and-build strategy, versus the challenging practical realities after acquiring and integrating five businesses
• Key considerations and questions you should ask before selecting a private equity partner
• The role of nano-technology in producing nanomedicines for effective targeting of disease…but also the challenges of dealing with this enabling platform
• Why there is cause for optimization for CDMOs when looking at the robust R&D funding environment and forecasted outsourcing growth

Harry has significant leadership experience with 20+ years in the pharma and biotech industry. He successfully transformed Pharmavize, a regulatory consultancy company into a leading CDMO, establishing a GMP team and infrastructure from scratch. Since 2015, he led the acquisitions and integration of five companies providing highly complementary services. He successfully integrated the service offering of the acquired companies onto one platform, creating the Ardena brand.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this special episode of Molecule to Market, we are marking our 100th episode! Join us as we look back, review our learnings and lay the land for episode 101…

For those that have been here since the beginning, we are incredibly grateful for your constant support and feedback. To our new listeners, thank you for joining the journey, seeing us through to 30,000 downloads and beyond. 

To our guests - thank you for being a part of this experience with us and taking the time to share your story. The podcast wouldn’t be what it is without the incredible guests we have come and grace the M2M microphone. With even more amazing thought leaders on the horizon and a special celebration coming to DCAT Week, stay tuned for a jam-packed 2023...

Your host, Raman Sehgal, switches seats with journalist Dan Stanton as host for a celebration of 100 episodes of the podcast. They discuss;

• The Molecule to Market journey and how the podcast has evolved
• Raman’s experience with securing a private equity deal for sponsor of the podcast, ramarketing, the business he started in 2009 
• Valuable lessons learnt throughout the process including; how to get the best out of a guest, what didn’t work so well as the podcast evolved and breaking the podcast formula 
• What’s to come for the podcast and Raman in 2023 and beyond…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the last 12 months in the life science industry.

He covers his 5 key trends from the year including:

• The biotech capital market slowdown and its impact on the outsourcing space
• Sustainability as the hot topic within the sector, from events to company practices
• Businesses operating in an increasingly digital way and what that means for the tech companies supporting them
• The cooling of mergers and acquisitions activity in the life sciences industry
• A reduction of discussion around Covid-19 as it moves into the sector’s rear view
  
  

Come back in 2023 for brand new episodes with great guests, including a special 100th episode celebration. Also, if you’re a previous guest, keep an eye out for an exclusive invitation in your inbox very soon…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with a look back to some of our early guests from the Molecule to Market archive.

Your host, Raman Sehgal, recaps his discussions on the pharmaceutical and biotechnology supply chain with:

• Stefano Console, founder and Senior Advisor at Oriento discussing: founding his business in Switzerland and the fractional management staffing structure that is helping Oriento succeed
• Claire Thompson, founder and CEO of Agility Life Sciences discussing: her career as a footballer and how it has helped her when successfully leading a team
• Jitesh Devendra, Managing Director at Solara Active Pharma Sciences discussing:  why it is crucial to invest time internally to be just as operationally focused as you are strategically focused
• Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics discussing: her do’s and don’ts for building new business partnerships

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sarah Stevens, SVP and Head of Early Development & Late Stage Commercial Operations at Quotient Sciences.
 
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sarah, covering:
 
Carving an incredible transatlantic CDMO career in traditionally non-female roles - balancing work, kids and breast cancer.
Words of wisdom for young women developing a career in the outsourcing space, including an appreciation of valuing the female perspective.
The concept of Translational Pharmaceutics® - delivering an agile and integrated offering for accelerating to first-in-human (FIH) clinical trials and optimizing dosage forms for proof-of-concept and beyond.
Potential impact of uncontrollable macro factors and current industry trends on demand for contract services and volunteer recruitment
 
Sarah is the Senior Vice President & Head of Early Development & Late Stage Commercial at Quotient Sciences, with oversight for all global sites and operational functions from early drug development programs through to late stage and commercial manufacturing. Sarah oversees deployment of Quotient’s unique platform for integration, Translational Pharmaceutics, which eliminates white space between these traditionally silo’d drug development areas. Prior to this role, she was the Vice President of Drug Development Sciences, with responsibility for drug development consulting and creation of integrated programs across the organization.
 
Located in Boston, MA, Sarah’s experience spans a range of scientific and leadership roles within the drug product contract development and manufacturing space. Sarah received her PhD in Pharmaceutics from the University of Manchester and her MPharm, Pharmacy from Strathclyde University.
 
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
 
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with independent life sciences consultant Jim Miller. Your host, Raman Sehgal sits down with Jim covering:

• The three biggest macro factors impacting the CDMO space right now
• How CDMOs and CROs are starting to feel the pain of emerging biotech’s funding woes
• What we can learn from the 08-09 financial crash that can help CDMOs/CROs during rockier financial times
• The cooling of M&A and company valuations, and why financial stability may become a more important selection criteria
• Where Jim would place his attention and money if he was running a CDMO...

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

As we celebrate the podcast hitting 30,000 downloads and approaching its 100th episode, Raman reflects on the most downloaded episodes with highlights from the top 5.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector, diving into the top 5 episodes of all time, featuring:

• JoyL Silva, Pfizer CentreOne discussing: her early career journey and advice, industry trends, and personalized medicines
• Tia Lyles-Williams, LucasPye Bio discussing: equality & diversity, Covid-19’s impact, fundraising and providing opportunities to the next generation  
• Gerry Cox, Velesco Pharma Services discussing: client relationships, starting a new business and his advice 
• Cory Lewis, INCOG BioPharma discussing: acquisitions, turning around a business, and lessons from the franchise model 
• Allan Shaw, Industry Consultant discussing: biotech trends, commonalities & challenges, and the supply chain ecosystem

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses emerging trends and challenges for the life sciences sector live from CPHI Frankfurt 2022, with:

• Grainne Hughes, Vice President of Business Support Operations at Almac 
• Christine Fürst, Senior Director Key Account Manager Europe at Vetter Pharma 
• Guido Wallraff, Corporate Business Development Director at Ardena
• Jenny Gattari, CDMO Business Development Lead (North America) at Pfizer CentreOne 
• Brittany Hayes, Director of Global Highly Potent & Oncology Platform at CordenPharma

Listen to this episode to find out more about these companies and gain an insight into the changes and demands they see coming in 2023. They also discuss their experience of CPHI this year, how it compares to last year’s event and what trends they have noticed across their exploration of the Messe. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses future industry trends live from AAPS Boston 2022, with:

• Casey Franklin, VP of Business Development at Alcami

• Umberto Romeo, R&D Manager at Corden Pharma

• Steven Dodd, Executive Director for sales strategy at Icon CRO

• Paul Dickinson, Founder & CSO at Seda Pharmaceutical Development Services

Raman finds out more about the exciting opportunities coming up for these companies in 2023 and beyond, as well as scoring the inside scoop on trends our guests foresee both within their business and the wider industry. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Katz, Founder & CSO at Sparrow Pharmaceuticals, Inc.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• The contrast of developing new drugs and running clinical trials in a big pharma versus his journey as the founder of a virtual biopharma company.
• What life really looks like and skills you have to develop in a firm developing novel, targeted therapies to address unmet patient needs.
• Some of the options, decisions and pathways to commercialization that a Phase 2 biopharma business has to consider.
• The inspiration, leadership learnings and brand influence of a famous Hollywood character.

Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan, earned MPhil and PhD degrees in Molecular Biophysics and Biochemistry from Yale University, and is an alumnus of Pomona College (BA, Chemistry). David has published over 50 peer-reviewed scientific papers and in his copious spare time, he is actively involved in new play development and is a glass artist.

Don't forget to subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason McKenna, Global President, and Dean McAlister, Executive Vice President both from Inizio Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with the dynamic duo, covering:

• A wealth of big pharma learnings for today’s emerging biotechs.
• The (good and bad) impact of the current biotech capital market slowdown on decision-making for outsourced service providers.
• What the future may look like in our space in terms of financing and therapeutic impact.
• Learnings from how to make a business relationship successes from complementary colleagues.

Jason spent the initial part of his career in big pharma, working for AstraZeneca in the US and UK across a variety of marketing, sales and finance roles. He is now the Global President of Inizio’s first enterprise business unit, Inizio Biotech. Jason and his team enable biotech partners to maximize the value of their assets by providing scalable support, through the seamless experience of a single point of coordination. Previously CEO at STEM, an Inizio Advisory company, Jason led the organization through significant scaling and transformation throughout the COVID pandemic.

Dean has over 35 years of biopharma experience across established and startup organizations – including 28 years with AstraZeneca in 16 roles of increasing commercial responsibility, where he led global and regional sales and strategic business development. Dean has built cross-functional teams spanning all therapeutic areas. Following AZ, he grew STEM Healthcare North America from 10 clients to 38 over a five-year period before a sale to UDG. He is also a podcaster, speaker, and published author.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this special episode of Molecule to Market, we go back inside the global drug development space with Marcelo Bigal, President and CEO, of Ventus Therapeutics, and Versant Venture Partner, who shares his journey from being a neurologist to taking a drug to market when he became part of Teva Pharmaceuticals and now is a CEO.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcelo, covering: 

• What it feels like to take a drug from the laboratory to market and what really goes into that process.
• The company’s phenomenal attitude toward patients and how this is exemplified in its drug development. 
• The incredible story of the company he joined and how 14 months after a fundraiser it was acquired by Teva Pharmaceuticals for $825M.
• The current state of the capital market and where future opportunities may lie for the business. 
• The challenging area of drug development in biotechnology over the last three years. 

Marcelo brings more than 13 years of pharma experience with a focus on urology spanning r&d, medical and scientific affairs. He has extensive experience in leading large and small scientific groups, including multiple leadership roles in industry, including the Chief Scientific Officer at Teva as well as Chief Medical Officer at Teva and Purdue. Prior to his work in the pharma sector, Marcelo was a faculty member of the Albert Einstein College of Medicine, Department of Neurology, as well as the director of research at the New England Centre for headache. 

He has authored no fewer than 330 papers in peer-reviewed journals, edited six books in urology and is the recipient of multiple awards and recognitions in the field. Marcelo holds a medical doctorate degree from the College of Medicine at the University of Sao Paulo, Brazil, where he obtained a master’s in science and a PhD in neurosciences. He completed his postdoctoral research at the New England Centre for headache.

In this special repurposed episode of Molecule to Market, we go back inside the global drug development space with previous guests Magnus Gustafsson, Board Member at Genovis, Jeff Dill, CEO at Vynamic. , and Peter Soelkner, Managing Director at Vetter to hear their thoughts on building a great organisational culture. 

Your host, Raman Sehgal, revisits discussions from past episodes, with amazing global guests who share their insights about building culture to give our listeners loads of takeaway points, from episodes including:

• Finland’s Viral Vector Manufacturer of Happinesses
  
  Hear from Magnus Gustafsson – who Raman describes as a delightful gentleman that remains passionate about his purpose. His curiosity has enabled him to take real pleasure from working across complex projects. Magnus cites investment into company culture as crucial to developing a great company and building a solid NPS score, commenting: ‘you need some of your own skin in the game’.

• Creating a healthy culture
  
  It’s no secret Jeff Dill is a favourite guest of Raman’s. During the pandemic they enjoyed a great conversation about culture and team work. Jeff firmly believes in prioritizing people and talks in detail about Vynamic’s ‘vitals’ – a document that incapsulates the company’s purpose and a series of values. The vitals provide consistency and a foundation to scale and build. He talks about doubling down on what works well to enable people to bring their whole selves to work everyday. What a great approach!

• From Pharmacy to $1B family-owned CDMO
  
  Finally, we hear from Peter Soelkner who contributed to one of our most successful podcast shows. We listen back to hear about Vetter’s phenomenal success in the US and Germany, and Peter’s fascinating thoughts on culture. From Vetter’s humble beginnings to earning a fantastic reputation in the space Peter talks candidly about the attributes and the people component that make the company so successful. Peter believes you should never look at how far you fell but instead at how high you will jump back up! 

Raman enjoyed the original conversations and took pleasure in listening back to bring you this special culture themed episode. It’s clear our guests all agree that culture is key to developing and scaling a great organization.

We’d love to know what you thought of this special repurposed episode and if you’d like us to develop more of them? Please share your thoughts with us and of course subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Evelyn Kelly, Chief Executive Officer at Orphan Drug Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Evelyn, covering:

• A deep dive into the world of orphan drugs, rare diseases and personalised medicines including the background, evolution and fast growth of the area.
• The revolution in drug development that we are living right now and what this means for CROs, CDMOs and vendors in the space.
• The scary phase of being a start up along with the importance of having purpose as your motivation and being prepared to step-up.
• The non-covid impact of covid of the health of the population and the set-back it caused for small biotechs.
• Pearls of wisdom for ambitious young female leaders navigating their careers in the pharma and biopharma space.

Evelyn has over 15 years’ experience in the pharmaceutical industry in both distribution and orphan drug companies, working across supply chain, quality assurance and management roles. Evelyn brings years of experience in manufacturing and distributing orphan and speciality drugs to over 50 countries globally.She specializes in the management of supply via virtual, outsourced models and has been named as both a QP and RP on multiple licenses. She has held various positions in Shire, NPS Pharma and PTC Therapeutics and has designed and ran successful supply chains for different products.Evelyn founded Orphan Drug Consulting in 2017, with the vision of supporting companies across the drug development cycle. She holds a Master of Pharmacy from Robert Gordon University and a Master of Business from the Irish Management Institute. She also acts as Adjunct Associate Professor for the School of Pharmacy, Trinity College, Dublin. In 2022, she was named as a finalist in EY Entrepreneur of the Year.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chuck Frey, VP Scientific Affairs at Coating Place. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chuck, covering:

• The backstory to Wurster coating technology and how it changed the world of formulation development.
• Being the go-to guys for the most challenging processing projects... when no one else in the market can.
• The advantages and disadvantages of going under the radar.
• Ups, downs, sacrifices and successes of family life while working in the industry.

Charles (Chuck) Frey is the Vice President of Scientific Affairs at Coating Place, Inc., a CDMO focused in Wurster (bottom spray) fluid bed coating and associated services.Chuck moved on to Coating Place, Inc. in 1999 to develop expertise on the Wurster fluid bed coating process. During his time at Coating Place, Chuck has focused primarily on application of the Wurster process and related technologies to meet the feasibility, formulation development, scale up, validation, and commercial processing needs of clients. Primary interests have included both formulation chemistry and optimization of process dynamics. The company continues to manufacture proprietary Wurster coating equipment for its operations and Chuck has helped maintain and expand the company’s offer with new fluidization plate designs, new nozzles, enhanced scaling knowledge, and other technical advancements. Having spent over 30 years in the sector, Chuck has also lectured on the Wurster process and formulations, and contributed several book chapters on the fluid bed coating processes and formulations.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Allan Shaw, Consulting CFO, Special Advisor & Board Member of several biotech companies. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Allan, covering:

• The sensitive cash position of biotech's as a ‘hangover’ after a decade of partying as the market was high.
• The potential domino effect and collateral impact of the biotech capital slowdown on the supply chain ecosystem.
• Core commonalities between biotech's of all shapes and sizes, and what challenges they face today.
• How CRO/CDMO and other pharma services’ vendors can add the most value during an expected bumpy ride for biotech's.

Allan is a senior biopharmaceutical executive and board member with 20+ years of international and transactional experience. He is a five-time public company CFO and has served on six public boards, which included the chairing of two audit and two compensation committees. He is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. Prior, Shaw also served as managing director and life science practice leader for Alvarez & Marsal’s healthcare industry group. He was also CFO at Serono.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this special episode of Molecule to Market, we go back inside the global drug development space with previous guests Go van Dam, CEO & Founder at TRACER,  Michelle Duggan, Inward Investment Manager, Invest North East England, Peter Soelkner, Managing Director at Vetter and Ross Burn, Chief Executive at CatSci.

Your host, Raman Sehgal, revisits discussions around trends in the biotech space, from episodes including:

• Physician. Scientist. Entrepreneur.
• The UK’s hidden life science gem
• From Pharmacy to $1B family-owned CDMO
• The opportunistic entrepreneur

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adrienne Leussa, Director of Ecosystem Partnerships at 54gene.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adrienne, covering:

• How the reality of the health challenges living in Africa as a child drove Adrienne into the drug discovery space.
• A rich insight into the only remaining high growth market globally for pharma companies.
• Learn about the main cities driving drug development growth within Africa and the prospect for more localised manufacturing.
• Life working for one of the leading biotech companies in Africa.
• Living life by curiosity as an ethos to make a lasting impact in the world.

Adrienne is a Biochemist (PhD) with 10+ years of hands-on experience and a plethora of diverse technical skills within the area of drug discovery and development. She has also worked as a lecturer and researcher in top African universities helping inspire a generation of scientists through access to information on the applications of biotechnology.She is fluent in 3 of the most used languages in Africa: Portuguese, French and English, and is ardent about continued learning, cross-culture collaboration, problem solving, customer service and mentoring.Adrienne’s mission is to elevate Africa through high quality, innovative, and credible scientific output for global prosperity.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Enloe, President and CEO at Societal™ CDMO. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Being at the birth of viral vectors and the-infant gene therapy field in the 90s... but choosing not to be there today. 
• After a career spent all over the world - he shares his pearls of wisdom of what he’s learnt from a lifetime of international business.
• Navigating business confusion and redefining companies from the inside out, while focusing on people and patients.
• Being a humble, humane, empathetic leader that does not take himself too seriously... and makes decisions quickly.
• Uncertainty around the capital markets and what this means to the CDMO space in terms of potential headwinds.

David has over two decades of executive leadership experience in biotechnology, clinical drug development, and GMP manufacturing.He was CEO at Ajinomoto Bio-Pharma Services, CEO at Althea CMO and also served as head of Lonza’s Viral Therapeutics Business Unit, which resulted from Lonza’s acquisition of Vivante GMP Solutions. Prior to that, he spent 14 years with a biotech company, Introgen Therapeutics, and played an integral part in taking the company through a successful IPO in 2020.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ata Tuna Ciftlik CEO at Lunaphore.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ata, covering:

• Bringing the next generation ‘satellite for tumours’ sequencing tools for immuno oncology and cancer research to drug discovery, and eventually the mainstream.
• Why life science start-ups need data to survive and thrive. And key lessons of entrepreneurship, from theory to reality.
• The avalanche effect - from a 2.5k competition fundraise to $50m in a market on-track to become $10b.
• Unmissable leadership lessons from PhD-start up to global life science business.

Ata Tuna Ciftlik was born in Ankara, Turkey. He received a double-B.Sc in Mathematics and Electronics Engineering from Middle East Technical University (METU) in 2006. He started interdisciplinary research at the interface of Microfluidics and Biology during his MSc studies in METU, where he received thesis of the year 2009 prize.

Next, he obtained interdisciplinary PhD in Biomedical Microfluidic Systems from Swiss Institute of Technology in Lausanne (EPFL) and was awarded internationally known Dimitris N. Chorafas foundation prize in the category of cutting egde technology.After inventing its core technology during his PhD, he has co-founded Lunaphore in 2014.

Lunaphore so far received USD 60 million financing from private and public sources, lead multiple innovation projects in Switzerland and Europe, counts close to 100 people, appeared more than 100 times in national and international media channels, claimed 22 awards and has consistently been selected as one of the best start-ups in the country. Ata Tuna is married, has 2 children and enjoys biking, running and hiking.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this special one-off episode of Molecule to Market, your host Raman Sehgal embarks on a solo cast to cover some of the major supply chain themes uncovered through Molecule to Market interviews.
The insights were originally delivered live on stage at CPhI North America 2022. Whether you’re a CDMO, CPO, drug sponsor or equipment vendor - this is not to be missed.Your host, Raman, covers:

• 4 main challenges the sector has felt over the last two years 
• 4 solutions we are seeing and that you may want to think about
• 4 trends you need to know for your business

Along with being the host of Molecule to Market, Raman Sehgal is the founder of PE-backed ramarketing, co-founder of Lead Candidate, and best-selling author of The Floundering Founder.Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses the pharmaceutical and biotechnology supply chain live from CPhI North America 2022, with:

• Robert Lee, President at Lubrizol Life Science Health - CDMO Division at The Lubrizol Corporation
• Lauren (Naughton) Hanna, Publisher at Contract Pharma
• Bob Macadangdang, Client Development Manager at Sharp, Contract Pharmaceutical Packaging
• Stephen Houldsworth, VP, Global Head of Platform Management & Marketing - Corden Pharma International
• Claire Robinson, Partnership Manager at Sterling Pharma Solutions

What are the biggest challenges in our space? What are the latest trends? What should you be aware of? Listen and find out what our guests think!

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Adam Wilson, President - BioPharmGuy. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adam, covering:

• The humble start-up story and journey of the biopharmguy.
• The pivot that took the website from being a job sharing site to one of the most widely-regarded and used platforms in the biotech world.
• The value of simply focussing on looking after your product as your fundamental market differentiator.
• Poking fun at the sector and being a source of entertainment as well as information.

Adam is the BioPharmGuy. Prior to running BioPharmGuy full-time, he worked as a Process Development Engineer at a public biotech, an FDA Investigator and a Lab Tech in a dermatology research lab at a nonprofit hospital. His various experiences have contributed to his knowledge of the biotech industry which has enabled BioPharmGuy to become the best biotech company directory in existence. He independently created and built BioPharmGuy.com which now receives 40,000+ unique visitors every month.

The website built around a database of information on biotech, pharmaceutical, medical device and life science companies around the world. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed. Your host Raman Sehgal is the author of The Floundering Founder.

Event season is truly well on its way and where better to start than Swiss Biotech Day, the leading biotechnology conference in Switzerland. Renowned for its innovative biotech start-ups and big pharma companies all in attendance, it was a great chance to meet experts from the life science industry from across Europe. Which is why it should come as no surprise that your host Raman Sehgal brought Molecule to market once more to the event space.

If you loved the ‘Memoir of DCAT 2022’ episode, this is a pod for you as he hit the event space again in style and interviewed some more great guests along the way. Listen to a diverse range of our guests’ thoughts during this event.

• Richard Collins, Managing Director Bio2Business Ltd
• Hanns-Christian Mahler, CEO at ten23 health
• Stefano Console, Founder & Senior Advisor at Oriento SA
• Philippe Tschopp, Head of Business Development CDMO Glatt

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Terry Novak, President & Chief Executive Officer at Salubrent Pharma Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Terry, covering:

• What he has learnt from 40 years in the pharma, biopharma and contract services space
• The best marketing technique - communicating constantly to your internal audience.
• The wave of orphan drugs that are driving demand for small scale and flexible manufacturing capabilities.
• How a focus on talent is going to make or break companies in the next 3-5 years.

Terry has extensive CDMO C-suite execution experience serving in numerous capacities. Terry has served on the Board of Directors of Pernix Therapeutics Ireland, Percivia LLC, American Red Cross Northern NJ Division, Patheon Puerto Rico, Frontline Pharmaceuticals, Curaxis Pharmaceuticals and is currently on the Board of Directors of Salubrent Pharma Services and Minutemen Life Sciences. Operationally, Terry has served as the CEO of Tedor Pharmaceuticals, COO of Pernix Pharma, President of Norwich Pharmaceuticals, President of Patheon North America, President of Frontline Pharmaceuticals and President of DSM.

During his 40 years in industry, he had built a track record of rapid turn-around success includes achieving consistent double-digit growth in revenues and EBITDA.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michael Kallelis, Chief Executive Officer at Mikart.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering:

• Growing up, studying and forging a career in Boston during the volatile biotech boom in Massachusetts.
• His hard-earned 40-years playbook of how to rebuild and revitalise a family owned business by respecting, studying and redirecting efforts.
• An insight into the under the radar but explosively vibrant life science scene in Atlanta, GA
• The role of a mid-market CDMO to drug development companies.
• The phenomenon hitting the North America healthcare market that you need to be aware of as it will impact CDMOs in the small molecule space...

Michael Kallelis has spent his career in public and private life science companies where he has successfully implemented commercial and operational growth strategies. Prior to Mikart, he held several senior roles including president of Exiqon Inc., co-founder and chief operating officer of Boston Biosystems, vice president of business development at KMC Systems, and general manager of several GE Healthcare businesses. 

His experience covers a range of technologies, including radiopharmaceuticals, gene expression analysis, medical devices, automated laboratory systems, oligonucleotides, specialty chemicals, biologics, and small molecules. Mike has been the CEO at Mikart since the fall of 2018.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ray Kaczmarek, Chief Executive Officer at Genezen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ray, covering:

• Translating military life lessons into key business leadership - taking care of your people, having operational discipline and allowing people to be leaders.
• Invaluable learnings from taking a drug from clinical trials to commercial and on-market supply.
• Insight into the booming cell and gene therapy space and how it will change the way we view medicine as a cure, not a treatment.
• The under the radar, up and coming region of Fishers, Indianapolis. Could this be the next big life science hub?

Genezen CEO Ray has over 25 years of leadership experience with the past 20 years in biotechnology and pharmaceutical operations. Ray has previously held positions including President at Nitto Avecia Pharma Services, Founder OC Biotech Consultants, SVP of GMP Operations at TriLink BioTechnologies, and VP of Manufacturing and Supply Chain Operations at Pacira Biosciences. He has supported new drug development, clinical operations, and commercial operations in biologics, vaccines, and pharmaceuticals throughout his career. Ray leads Genezen’s growth strategy and is focused on finding ways to achieve excellence for our employees, our clients, and their patients.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hans J Johansson, Global Applications Director at Purolite. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hans, covering:

• A career spent developing ideas and creating products that produce new applications for customers and commercial success.
• Driving the Purolite business unit from the ground-up from a lab bench to a commercial scale life science based franchise.
• Hans’ lifelong habits and approach that have enabled him to have a successful career.
• An insight into Sweden’s vibrant life science hub - Uppsala.
• The development of new technologies that will increase yield while reducing environmental footprint... a sign of things to come!

Hans J Johansson is Global Applications Director at Purolite Life Sciences, Llantrisant, Wales. He has spent more than 30 years in the Biotech industry. Most of the time in research and development at Pharmacia/Amersham/GE Healthcare with a special focus on design and applications of industrial chromatography resins intended for antibody purification. He frequently publishes in scientific journals and is the holder of more than ten patents around resin design and large-scale protein purification. He is currently working with development and applications of novel, agarose-based, chromatography resins.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Hall, President at Lifecore Biomedical

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: 

• What a period working on the sponsor/buyer side taught him about getting best out of your CROs and CDMOs

• The challenges of doubling in size twice in just 10 years and not getting ‘too far out over your skis’
• Building a culture with longevity and not losing sight of the purpose - never hurting a patient
• Insight into market growth figures and why the injectable market remains a hot spot
• Timeless advice around not chasing the money, always be learning and keeping an open mind

Jim was appointed President in June 2017. He served as Vice President and General Manager since July 2013, Vice President of Operations since 2006 and was Director of Manufacturing Operations and Engineering since 2001; prior to that he was the Manager of Engineering and Operations at Lifecore. Mr. Hall brings over 30 years of pharmaceutical and combination product manufacturing and development experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

Last week marked the return of DCAT in New York City. A prestigious event that’s open to companies engaged in the Biotech and Pharmaceutical manufacturing space…

With the massive return this year of events. Your host, Raman Sehgal, decided to shake things up this year and do things differently, taking your favourite life science podcast Molecule to market with him… Equipped with only a laptop and a microphone, he hit the event space in style and interviewed some great guests along the way.

Listen to a variety of select guests at the top of their field. 

• Yasmin Davoodi, Head Of Commercial at ramarketing

• Jon Lenihan, Head of Sales & Business Development, CDMO Business Unit Head at Emergent Biosolutions

• David Enloe, President and CEO of Societal™ CDMO (formerly Recro)

• Gil Roth, President, Pharma and Biopharma Outsourcing Association

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Magnus Gustafsson, formerly at the time of recording Head of Global Business Development now Chief Business Officer at Biovian.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Magnus, covering:

• The advantages and disadvantages of viral vector products, including the challenge of needing to balance cost with patient access.

• Insights into a CDMO with a 96% staff retention rate and an enviable NPS score.

• The ballooning opportunity that exists in the viral vector space but also the risk that potentially comes along with such a popular platform.

• What makes Finland and the Nordic region so special?

Magnus Gustafsson has worked in the biopharma manufacturing space for over 20 years. He holds an MSc in Biochemical Engineering, an MBA in Business Administration and a PhD in Medical Protein Science. Having worked for the likes of AZ, GE, Recipharm and Cobra Biologics, he has a track record of driving business with both commercial and strategic success combined with a customer-centric mindset. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Hanns-Christian Mahler CEO at ten23 health.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Hanns, covering:

• Transitioning from the structure and scale of Merck, Roche and Lonza into an entrepreneurial start-up CDMO leader.
• Having a business purpose focused on the triple-bottom line that is not just profit - patients, people and planet.
• Tips and insights of how a CDMO can play its part in encouraging sustainability, reducing environmental impact and managing footprints, across all levels.
• Insights into the opportunity and growth in small-scale sterile biologics, and some of the drivers behind these trends.
• Dr. Mahler is CEO & Board Member at ten23 health. He previously led the Drug Product Services (DPS) Business Unit at Lonza and worked in various leadership roles at Roche and Merck. He has an extensive expertise in formulation development, process development & validation, packaging/device development and integration, sterile manufacturing, and regulatory submissions.

With a Ph.D. in toxicology, he also serves as Editor for Pharmaceutical Research, Journal of Pharmaceutical Sciences, AAPS Open Journal, and PDA Journal of Pharmaceutical Sciences & Technology. He has published more than 120 manuscripts and is co-inventor of more than 50 patents.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Leitham, Senior Vice President and General Manager at Aspen Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Why a transformative approach is now needed to better deal with new therapeutics and modalities.
• The pandemic as the inflexion point for companies in pharma to truly adapt technology and create a competitive advantage.
• How contract services organisations are driving change in the life science sector and why they could be the ‘lighthouse’ for others to follow.
• Being open to failure, embracing the wrong calls and treating every set back as a learning opportunity.

David leads the pharma business unit at AspenTech, defining solutions that best serve the needs of pharmaceutical manufacturers to accelerate digitalization in their environments.

Prior to AspenTech, David spent nearly 20 years with Thermo Fisher Scientific. 

He held multiple leadership positions, most recently as Vice President and General Manager responsible for a team of more than 500 people. In this role, he drove digital transformation efforts for multiple businesses within the company, while also integrating and harmonising product divisions for improved organisation and performance.

His previous roles include Glaxo SmithKline where he served as Vice President, Information Engineering, Technology and Architecture. David attended Penn State University where he holds a Master of Science degree in Software Engineering, and a Bachelor of Science degree in Aerospace Engineering.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jaqueline Escotero, Regional Vice President for Latin America at World Courier.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jaqueline, covering:

• The misconnections, characteristics and challenges of doing business in Latin America’s pharmaceutical sector.
• The immense complexity and level of responsibility involved in vaccine storage and distribution over the last year.
• Timeless lessons from a lifetime spent doing international business all over the world.
• A key trend that everyone in our sector needs to be prepared for in a post-pandemic world.

Jaqueline is responsible for the World Courier business in Latin America and is based in São Paulo, Brazil. She is an experienced executive, with 29 years of international experience in the healthcare industry, leading important roles in marketing, sales, training, government and external affairs, specialty logistics and customer service at major pharmaceutical and medical device companies. She holds an MBA in Strategic Marketing and Bachelor Degree in International Business. She is also the global Chairperson of WIN - “Women’s Impact Network” - at AmerisourceBergen, a global initiative, focused on over 40,000 employees.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ross Burn, Chief Executive at CatSci.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ross, covering:

• Creating a successful business from an opportunistic AZ spin-out.
• Never being afraid to pivot in-line with the needs of the market and have big aims like becoming an innovative medicines development partner with a $1 billion valuation.
• The challenge of raising capital as an oversubscribed CRO with a 50% compound growth rate.

How the pandemic has helped put life sciences and pharma R&D on the map but also the work to be done to meet unmet needs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this special bonus episode of Molecule to Market, our host discusses his very first book launch ‘The Floundering Founder’ which is now available on Amazon and Kindle. 

Whilst you know him as the host of Molecule to Market, Raman has built up an impressive career in marketing, leadership and sector disciplines over the past 20+ years working within the global pharmaceutical and biotech outsourcing sector. Over the past twelve months of that career, Raman has spent an hour each day working on his latest achievement: ‘The Floundering Founder.’

The Floundering Founder gives 24 lessons to refocus your business and better yourself.  

With quick, simple lessons, The Floundering Founder can help you re-engineer your business and your life for sustainable, long-term success.

In twenty-four bite-sized lessons that fit any schedule, you’ll learn to navigate forward with renewed intentionality and purpose.

Make no mistake, this book isn’t fictional. You will relive the close and personal revelations of starting and scaling a business and how ramarketing has grown to be one of the most fast-growing global marketing agencies. 

To purchase visit:

UK link is here

US link is here

We would love to hear what you think of the book! Please write us a review to let us know what you think in the review section.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Soelkner, Managing Director at Vetter.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The fascinating and humble origin story of one of the world’s most well respected sterile filling specialists.
• Peter’s journey of leading Vetter in becoming a $1bn, 5500 person family-owned CDMO...alongside a fellow Managing Director.
• How the DNA of a culture becomes a critical competent of global business growth and consistent client delivery.
• Key future industry trends, including the challenge of preparing for the ‘colourful scenery of biotechs in the next 10 years’ - meaning the need to have the flexibility to deal with ultra orphan drug products and high volume products needing high speed lines.

Peter Soelkner has been a Managing Director of Vetter Pharma-Fertigung GmbH & Co. KG since June 2008. In 2009, he was also appointed Managing Director of Vetter Pharma International GmbH, the company’s marketing and sales organization. Soelkner graduated from the University of Dortmund, Germany, in 1992 with a degree in chemical engineering and earned an MBA from Columbia University, New York, in 2001. Before joining Vetter, he held positions in Germany and North America at Sartorius AG and Sartorius North America Inc., in R&D, marketing, key account management, and general management roles. At Vetter, from 2003 to 2007, Soelkner managed the company’s key account program and global end-to-end supply chain. He left the company for a year to serve as Vice President of global key account management at Sartorius Stedim Biotech (USA) before returning to Vetter in 2008.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this special roundtable episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

Jean-Jacques Mondoloni, Managing Partner WOMBAT CAPITAL

Mark Quick, Executive Vice President Corporate Development at Recipharm

Gerry Cox, Vice President at Pace Life Sciences

Your host, Raman Sehgal, discusses M&A trends in the pharmaceutical and biotechnology supply chain, covering:

• What a real-life M&A deal in outsourcing looks like from the buyer, seller and advisor angle.
• How the dynamics of M&A have changed over the last decade given the fragmented marketplace alongside increased funding, PE-interest and a pandemic spotlight now on the sector.
• Dizzying multiples, the fight for assets and key factors driving deals and valuations in contract services.
• Predictions from the panel around the future of deal flow in the outsourcing space... will the current velocity continue?

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michelle Duggan, Inward Investment Manager, Invest North East England.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michelle, covering:

• Why is North East England becoming a UK hot spot for Health and Life Sciences.
• Collaborating and breaking down barriers to help create a super cluster of life sciences.
• The academic and industrial heartbeat that makes the region so attractive to CDMOs and major supply chain players.

Michelle Duggan has been an inward investment manager at invest North East England since January 2021. In 2016 to 2020 she was previously appointed as Partnership manager of Newcastle University where she was responsible for cultivating and maintaining relationships among business partners. 

Her devotion to the North East is unmatched across her extensive career. With her other previous position as economic advisor at North East Local Enterprise Partnership she helped place where businesses invest, grow and prosper - delivering more and better jobs for everyone.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Eccles, Chief Executive Officer at ChargePoint Technology. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:

• The journey from a management buy-out (MBO) to running a £20m,100-person, global business.
• Benefit of investing in technology within sterile environments to avoid cross contamination and prevent expensive downtime.
• A perfect storm of market factors that are driving demand for ChargePoint and its products, including the explosion of facility investments in the CDMO space.
• The shift towards single use technologies yet the need to combat plastic usage. And how sustainability will become a core business issue and a major valuation metric for buyers.
• An inside look into the virtual process of ChargePoint’s recent acquisition by Arcline Investment Management and the dizzying level of buyers that were in the running for the fast-growing business.

Chris has managed the global business expansion of ChargePoint across all functions including offices based in the UK, Europe, America and Far East. His background in manufacturing management and precision engineering was instrumental in determining the strategy to outsource manufacturing through strategic acquisitions and equipment investments, including the investment in cleanroom technology and disposable manufacturing processes in 2019 and the managed recruitment of technical resources.

As CEO of ChargePoint, Chris has developed a strong positive culture within ChargePoint, focussed on honesty, integrity, and quality which is ultimately reflected in customer satisfaction, employee retention. And the recent successful acquisition of ChargePoint by Arcline Investment Management.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Go van Dam, CEO & Founder at TRACER.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Go, covering:

• The value of micro-dosing and fluorescent imaging in small patient populations at the preclinical proof of concept phase, and the benefits to investors, biotech and big pharma.
• The journey of stepping out of the operating theatre and into the boardroom. Taking an idea from the academic breeding ground and scaling into an industrial level so it has greater application.
• How the academia and industry ecosystem can collaborate, share and partner for the greater good.
• The need to observe, talk and learn from others. And it’s OK to copy and paste what you like in others.

Prof. Go van Dam is the CEO and Co-Founder of TRACER, a Clinical Research Organisation specialising in generating fast and accurate in-human data with nuclear and optical molecular imaging techniques, even before the classical Phase I-III studies. Go is seen as a pioneer in the optical imaging field with groundbreaking research to his name. 

Go originated as a surgeon oncologist and professor of Surgery at Groningen University. He trained at Harvard, the Mayo Clinic and NCI. Go executed and published the 1st in-human application of targeted fluorescence imaging in 2011 (Nature Medicine) and published more than 140 papers predominantly about clinical translation of innovative targeted optical molecular imaging. He currently focuses on utilising his validated optical imaging expertise in the life sciences industry to reduce R&D innovation costs, shorten time-to-market, and increased efficiency for innovative drug development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Devendra Mishra, Executive Director and Founder at Bio Supply Management Alliance (BSMA).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Devendra, covering:

• Being at the birth of biotech becoming a business and creating a network of 10k+ supply chain professionals.
• How we have just been through the most creative and productive period in healthcare in the last 100 years. Government bodies, private companies and academia collaborating to break down barriers and accelerate growth.
• The similarities of developing a movie and developing a new drug product. And what the life science supply chain can learn from digital collaboration and data analytics that occur in Hollywood.

Devendra is an internationally recognized authority on supply chain management thinking and practice. For two decades he has been committed to the adoption of disruptive technologies in media and entertainment as well as life sciences as an adjunct professor of Supply Chain Management at Pepperdine University.

Since 2004, the Mission of BSMA has been to advance the supply chain of Life Science through collaboration and adoption of technology. Positioned in the USA, Europe and India, its members are all the major biotech and pharma companies of the world.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com 

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hogan, External Manufacturing Team Lead for the Americas at Bayer Pharmaceuticals.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Daniel, covering:

• Managing a portfolio of 30-50 CMO partners across OSD, aerosols, topicals and liquids. And why due diligence and careful CMO selection is vital given its 10 x harder to exit a site.
• Some of the fundamental differences and similarities between sourcing as a big pharma and a small biotech.
• What good and bad relationships look like with an outsourced partner.
• The proliferation and availability of vendors in the outsourcing space. And why there is always room for CDMOs/CMOs with novel capabilities.
• Timeless advice for CDMOs/CMOs/CPOs in building relationships and revenue with big pharma.

With almost 20 years in the sector, Dan’s technical knowledge encompasses diverse pharmaceutical dosage forms with experience manufacturing and formulating a wide range of products for oral, topical, and parenteral administration. He thrives on contributing to complex products with the potential to cure people of disease, enabling them to lead lives of health and wellness.

Leading a team of experienced engineers responsible for the technology interface between Bayer and Contract Manufacturing Organizations (CMOs), Dan currently manages the manufacturing of a diverse dosage, multimillion-dollar product portfolio while providing guidance on activities such as process optimization, technology transfer from Bayer research and development to CMOs and validation of processes at commercial scale at various CMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Grant Merrill President & CEO at AES Clean Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Grant, covering:

• Becoming the leader of the business that he dreamt of representing.
• The need for cleanrooms to work in an invisible way as the most critical square footage at the core of the facility.
• Having to keep up with demand during the pandemic with the swelling production needed due to covid vaccines.
• The new therapeutic areas that are driving market growth and the need to let science flourish.
• Why the CMO space is poised for growth in both drug substance and drug product.
• The simple but magical abilities of being able to communicate and building personal relationships.

Grant Merrill has been involved with cleanroom design and construction for over 25 years. He earned his BS in Mechanical Engineering from Cornell University, and then immediately entered the world of critical facilities and the mechanical systems that support them. After a successful career in the industrial HVAC engineering business, Grant joined the AES team 20 years ago. Now as President & CEO, he leads multi-disciplinary teams to deliver complex cleanroom facilities to clients throughout the life science industry.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed. 

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Carl Turner, Vice President Supply Chain at Mayne Pharma.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl, covering:

• Managing 30+ CDMOs across several drug delivery systems and having the unique perspective of being on the buy CMO side, but having visibility of the CMO sell side.
• The 4 Cs that Carl looks for in sourcing, evaluating and selecting a new CMO partner. And what a great vendor relationship looks like
• The constant balancing act of risk mitigation and achieving economies of scale in using third party vendors.
• The impact of globalisation on product supply and the value of having plant-level contacts and communications.

Carl has almost three decades of experience in the pharmaceutical sector. A biologist by trade, he worked his way up the ranks at Abbot for 12 years in operations. He then made his way into planning and supply chain operations during 11 years with Hospira (became Pfizer). He has spent the rest of his career at Mayne Pharma helping the Australian-headquartered pharma company manage its complicated clinical and commercial global supply chain.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

In this special events-themed episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Samuel Thangiah, co-founder of Life Science Integrates
• Tara Dougal, Head Of Content & Insights for Pharma at Informa Markets
• Edward McNamara, Vice President of Innovation Banking - Life Sciences at Cambridge Trust and the Co-Founder of BioXchange

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology event scene with his three guests, covering:

• The impact on event organisers and the pivot required over the last 18 months including the birth of the smart/hybrid event model.
• The side effect benefits of virtual events including international reach and even better speakers.
• A look forward to what local, regional, national and international trade events may look like in the future. And, how you and your organisation should be thinking about, approaching and planning for events in 2022.

Samuel is Co-Founder and Executive Director of Life Science Integrates. Life Science Integrates produces the debate-led events shaping conversations in Pharma, BioTech and MedTech.

Tara is Head of Content and Insights for the Pharma Portfolio at Informa Markets, where she has worked since 2015. In this role, Tara leads the digital and live content strategy for CPhI Worldwide, Pharmapack Europe and CPhI North America.

Ed is Vice President of Innovation Banking at Cambridge Trust and has both a life sciences and banking background. Prior to joining Cambridge Trust, Ed worked on business development for Biotech Vendor Services. Ed also co-founded a very successful networking group, BioXchange

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Martino Picardo, Chairman at Discovery Park.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Martino, covering:

• His ‘three careers’ over the last few decades, mainly spent translating science into commercial entities that make a difference.
• Building Stevenage Bioscience Catalyst from the ground-up from the middle of the golden triangle through relationships, partnerships and networking.
• The ‘holy trilogy’ of building incubators from a blank sheet to successful, thriving communities.
• Creating a life science village from a transitioning Pfizer R&D site in the UK into an ecosystem with 160 companies.
• Never being a better time to work in life sciences and for entrepreneurs to thrive in the ecosystem.

Martino is Chairman of Discovery Park and an Independent Consultant. With a a PhD in Biochemistry, Martino spent almost a decade with Amersham International after his time in academia.

He was the first CEO of the Stevenage Bioscience

Catalyst an ambitious concept to develop an Incubator and Accelerator, which is now as world class Science Park.

A former Entrepreneur in Residence at UMIP, Manchester and with the NHS, Martino is also on Board of BIONOW, and is Chairman of VisusNano Ltd and Evidential Ltd.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

After years of frustration with recruitment service providers in our space and seeing many of my CRO/CDMO connections miss their growth targets because their talent agenda just can’t keep up, I decided to create a talent sourcing solution for pharma & bio outsourcing. Proudly introducing, Lead Candidate.

The business has been founded purely to support ambitious, growing CROs, CDMOs and pharma service firms. Lead Candidate aims to help address many of the common issues we see guests talk about - attracting people into industry, improving diversity in our sector and simply being better prepared for growth.

For many years, I strongly believed there was a need for long-term, responsible, talent acquisition from people who genuinely understand the intricacies of our industry. And a firm that would also take responsibility for championing careers and treating people with respect. 

Whether you’re looking to build your team or find your next move, visit Lead Candidate and get in touch with the team.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug product and sterile injectables sector with Cory Lewis CEO and President, Founder at INCOG BioPharma Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Cory, covering:

• The incredible 10-year journey of Cook Pharmica from a burning cash turnaround challenge to a $950M acquisition by Catalent.
• Customer-centric lessons learned from the franchise business model that’s being adopted by a CDMO start-up.
• The continued growth of the sterile manufacturing space in North America and several growth drivers.
• Life as a founder of a CDMO start-up after 25+ years as a senior industry exec.

Cory has spent 25 years in the CDMO space. After a spell with Baxter, he served as vice president of business development and marketing for Cook Pharmica until its 2017 sale to Catalent for $950M. He has since founded INCOG, a start-up CDMO that is investing $60M to build its 90,000 square foot headquarters in Fishers, Indiana and hiring about 150 people by the end of 2024.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dr. Louise Duffy, Ph.D., SVP and Head of the Scientific Project Leaders at Abzena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Louise, covering:

• Learnings for CDMOs after almost three decades spent with big pharma. 
• How to balance the juggling act between dealing with hundreds of projects, clients, and systems as a fast-growing large molecule CDMO.
• Why the speed of innovation has massively increased in pharma and biopharma over the last 10 years.
• Tips on how to improve your presence and move forward quicker as a female leader.
• The importance of closer-knit supply chains involving originators, CDMO, technology, equipment, and material providers in developing increasingly complex molecules.
• The trend towards customised molecules with exquisite targeting and greater government interest as consequence of Covid.

Dr. Louise Duffy is a Senior Executive with an extensive background in the global bio/pharmaceutical industry with experience in business development, strategy, R&D, operations, and supply chain. She has more than 30 years’ experience in the industry, including increasing responsibilities at GlaxoSmithKline and Janssen. With broad CMC and regulatory experience and specialist knowledge in personalised medicine, biochemical engineering, chemistry, and biological sciences Louise is SVP and Head of the Scientific Project Leaders at Abzena.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sébastien Ribault, Vice President & Head of End to End CDMO Services, Process Solutions at Merck Life Science.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sébastien, covering:

• The ever-changing world of biotech and how things talked about 20 years ago are now becoming a reality for many treatments. 
• Re-inventing the drug development process when faced with the 'Everest' of taking a covid treatment from bench to production in just nine months. 
• Learning to ask those around you: "If you could do things differently - what would you do?" as a way of unlocking innovation and challenging the norm.
• The wave of personalised medicines and treatments on the horizon and the need to develop the tools to bring down costs and make them more accessible.

With a PHD in Molecular & Cellular Biology, Sébastien has been in the biotech space for almost 25 years. He has spent the bulk of his career at Merck Life Science where he has progressed to the position of Head of End to End CDMO Services for Process Solutions.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! 

Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile, and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vanessa Elharrar  PPD, VP, Vaccines Business Strategy Lead, at PPD Vaccine Clinical Development and Medical Affairs.  

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vanessa, covering:  

• Being at the centre of vaccine development and patient distribution over the last year. And the global pandemic’s role as a day of reckoning for the sector to do things differently in terms of virtualisation of trials becoming the norm.
• How MRNA vaccines could be the key to helping in HIV research and supporting patients at risk of AIDS.
• Carving a career path aimed at making the biggest impact on the global patient population.
• The need to be better prepared for future pandemics in terms of better better disease surveillance and detection, but also stockpiling vital equipment and having local vaccine manufacturing capability.
• The increasing trend towards CDMOs and CROs merging to offer a complementary and unified offering to help clients reduce timelines.

An MD/Doctor by trade, Vanessa now leads early engagement with Vaccine sponsors and offers strategic guidance in the development and implementation of vaccine trials. Her areas of expertise include COVID-19 vaccine development and medical monitoring of vaccine studies and HIV biomedical prevention. She is Board Certified in Preventive Medicine and Public Health having completed a Masters in Public Health at The John Hopkins University. If that was not impressive enough, Vanessa is also fluent in French, Spanish and Hebrew.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with JaeB Kim, Managing Director at Samsung Biologics America.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with JaeB, covering:

• A year at one of the largest and fastest-growing CDMOs in the world.
• Growing a US presence within the thriving biopharma cluster in San Francisco Bay with ambitious plans for future expansion.
• The need for industry to ‘give’ in order to ‘take’ from innovation in academia, along with the pivotal role that collaboration has played during the pandemic.
• How Covid-19 has ‘tested the system’ from R&D to logistics and patient supply and how this will enable the sector to be better prepared for a more orchestrated response to future pandemics.

JaeB is a senior life sciences professional with 15 years of experience in biotech and biologics manufacturing. With an MBA and a PhD in Cancer Biology, he worked for PerkinElmer before joining global CDMO giant Samsung Biologics in 2020. JaeB is also an Adjunct Assistant Professor at Michigan State University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Urvish Pandya, Managing Director at Allotrope Scientific Ltd.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Urvish, covering:

• The exponential growth of chemistry in India leading to the production of many fine Indian chemists all over the world.
• Honest advice on how to deal with being made redundant as a result of being caught in the crossfire of M&A in the outsourcing space.
• The role of guiding drug sponsors in finding the right CRO and CDMO match, then getting the best out of them as a partner.
• The need for more modular and flexible capabilities in later stages of the drug manufacturing process.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Andrew Moore, General Manager at Pfizer CentreOne.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Andrew, covering:

• The pride of being part of Pfizer in the last year and first-hand experience of working with CEO Albert Bourla.
• Lifelong leadership lessons learnt during eight years of military service in Iraq, where decisions cost lives.
• Being the only black guy in the room 99% of the time and the seriousness of being a black leader and the need to drive diversity for better business outcomes.
• Pushing yourself outside of your comfort zone by going from the corporate life to a ‘roll your sleeves up’ CEO at a university spin-out.

Andrew is an experienced healthcare leader and entrepreneur, who began his healthcare career in sales and marketing, including seven years at Pfizer. He has also held leadership roles Baxter, AmerisourceBergen and McKesson. Most recently Andrew was the CEO of AI start-up CogxVision before rejoining Pfizer. Prior to his professional career, Andrew served in the U.S. Army where he received multiple accolades, including the Bronze Star for his combat experience in Iraq Desert Storm.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tom Moody, Vice President of Technology Development and Commercialisation at Almac.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• 20 years at Almac and being on a journey that has seen the company go from a few hundred staff to over 5500 people.
• The chemistry of today is not the chemistry of tomorrow, including the future impact of flow chemistry and the need to bring new technologies together.
• The importance of giving back to the community and inspiring the next generation of scientists.
• Reinventing yourself as a way to keep you on your toes

Prof. Tom Moody is the Vice President of Technology Development and Commercialisation at Almac Sciences. His work has earned him numerous accolades and he is co-author and author of over 60 publications and patents. He is a strategic leader and technical expert in chiral chemistry and biocatalysis with more than 20 years of extensive academic and industry experience.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Bigelow President at xCell Strategic Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The transition from being on the big pharma sponsor side at Pfizer to being head of one of the world’s biggest CDMOs.
• The challenging of adding a development capability to well-oiled manufacturing infrastructure and way of working.
• They key buying criteria emerging pharma considers when choose a CDMO.
• Increasing consolidation and fragmentation in today’s outsourcing sector due to continued market growth and the explosion of new technologies.

Pete is a very well respect industry leader having spent over 25 years in the global pharmaceutical manufacturing space. He was at Wyeth and then Pfizer for the best part of 15 years before becoming the interim CEO and President of North American operations at Patheon. He since moved into management consulting before establishing his own firm called xCell in 2014.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Steve Ferguson, Chief Executive Officer at Medix Biochemica. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:

• The positive and negative impact of Covid-19 on the diagnostic sector. And the need for more spend on diagnostic sector moving forward.
• How his humble and grounded upbringing gave him an early respect for the strength of women and gender equality.
• Simply the importance of having fun, enjoying yourself and making a difference at work. Otherwise, what’s the point?
• The importance of creating visibility in a fragmented segment of the outsourcing space and then overlaying relevance to the buyer.

With around 25 years’ experience in the life science sector, Steve has worked for the likes of Lundbeck and Thermo Fisher before joining Medix Biochemica at the CEO. He is an expert in the pharma and diagnostic space and well-respected industry leader.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Archie Lovatt Life Sciences Biosafety Scientific Director at SGS.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Archie, covering:

• Being motivated by saving lives and seeing your contribution make a real impact on the world. Following your heart and not chasing the money.
• Seeing Covid-19 drugs developed in a parallel rather than sequential way, helping accelerate the process while not compromising on safety.
• Being acquired by SGS yet maintaining the entrepreneurial spirit to explore and innovate.
• The long term value to patients of now having more platform technologies and a greater operational infrastructure to deal with disease areas.

Archie is a vaccine, gene and cell therapy biosafety testing expert. He graduated with a PhD in molecular microbiology and has been in the industry for the best part of 30 years. During this time, he founded a CRO called Vitrology, which was then acquired by SGS in 2012 and has since served on the board as Scientific Operations Director. He was also voted into the top 100 most influential people in human medicine development and manufacture.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeff Dill, CEO at Vynamic.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeff, covering:·    

• How to create, document, grow and internationally scale an incredible business culture.
• The shift towards greater industry collaboration as an important step for quicker drug approvals in the future.
• Servant leadership philosophy - to listen, be empathetic and enable.
• The drive and transparency needed to create a more diverse and inclusive workforce.

Jeff boasts over 20 years’ experience in the healthcare consulting world. Previously at Accenture, Jeff joined healthcare industry management consulting firm Vynamic in 2005, he has been there ever since and is now the CEO.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal Founder & Global President of ramarketing & usual host of the Molecule to Market podcast.
 
Raman has 20+ years of marketing and life science industry experience. Starting his career and setting up his business in the UK, Raman now resides stateside after relocating to the US to open an office in Boston. Raman previously worked for The Specials Laboratory and SCM Pharma before setting up and leading ramarketing globally.
 
In this special 40th episode, Raman is handing over the microphone and questions to his friend and returning guest Dan Stanton, Editor at Bioprocess International and Managing Editor at Xconomy. Your guest host is turning the tables and using his journalistic experience to present the show.

In this episode Dan and Raman chat about the evolution of ramarketing, going global and the cultural differences and risk adversity between UK and US business styles. They also discuss how a people-centric approach enabled ramarketing to flourish and offer up 7 timeless tips for handling PR. You will also hear how Raman’s early childhood experiences instilled his strong work ethic and took him from being a playground confectionary supplier to become a successful entrepreneur and global agency owner working across the life sciences and pharma sector.

Hear Raman discuss:
●     His early life and where his business ethic came from.
●     How his marketing expertise led him to become an ‘accidental agency owner’.
●     Why his playground entrepreneurial spirit defined him as a businessperson.
●     The value of developing a people-centric business & why you shouldn’t burn bridges in business.
●     7 timeless tips for working with journalists.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Gerry, covering:    

• The transition from two decades in Big Pharma to the entrepreneurial world of running a CDMO.
• Becoming known as the ‘lab down the hall’ for many clients with products in the clinical phase of development.
• The value of talking to people, networking and not being intimidated when starting out your own business.
• Consistently keeping your operational house in order in the face of increasing market demand.

Raman has taken great pleasure in getting to know fellow Bostonian Gerry, since moving to the states. An accountant by trade, Gerry worked for Pfizer for eighteen years in corporate and research & development roles, both globally and onsite. Since founding Velesco back in 2007, he has led the steady growth of the company’s operations and its most recent expansions. A phenomenal networker, Gerry enjoys connecting people and communicating with people within the sector.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Megan Greth, Director of Marketing & Business Development and Tadgh Prendeville, General Manager at ARx LLC.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Megan and Tadgh, covering:

•     The developments & demands for new transdermal drug products and oral thin films as a more patient centric drug delivery platform.
•     How the focus on Covid-19 related vaccines directly impacted the drug product supply chain.
•     ‘Lean’ observations on the speed (or not) of the pharma manufacturing sector.
•     Reflections on the career ‘ride’ and the sectors core focus – making drugs for sick people.
•     Learning to not sweat the small stuff and to ride out any storms.
•     Chicken-and-egg capacity and capability challenges for CDMO investment as clients edge closer to commercial approval.

Who are the ARx duo?

With a Bachelor of Science, Megan has been in the sector for around 15 years. She is now responsible for market assessment and strategic selection of new projects that will benefit from ARx’s drug delivery technologies. Whilst Tadgh has a background in bioengineering and has worked in manufacturing and operations and as a lean consultant, before progressing to his current role as head of ARx.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jarlath Keating President & CEO at ABL Inc.

Jarlath has over 25 years of global life science industry experience. Starting his career in the UK in the early 90’s before transitioning to the US in 2009. During this time, Jarlath worked for HyClone and Lonza Biologics. He served as the Vice President of Global Commercial Operations for MilliporeSigma’s Process Solutions Services division, leading the BioReliance® biological safety testing and biomanufacturing divisions. He now leads ABL, globally.

Your host, Raman Sehgal, leads a conversation on the pharmaceutical and biotechnology supply chain, transitioning from ‘shop floor’ to CEO, and the impact of COVID-19 from a manufacturing point of view. Hear Jarlath’s thoughts on:

•     The importance of leaders building knowledge across the whole business.
•     Understanding the jigsaw - your success is dependent upon the success of your colleagues.
•     Taking opportunities, leaning into risk, and backing yourself through belief and hard work.
•     The evolution of the gene therapy and cell therapy space, and the operational challenges it brings.
•     How contract service providers must anticipate rather than react to future pandemics and new areas of development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Richard Johnson, Founding Director of Upperton Pharma Solutions. With more than 25 years of experience in the industry, Richard is a founding director of two, successful pharmaceutical companies. He has authored 30 scientific publications and is the named-inventor on more than 20 patents. His research experience spans a broad range of scientific disciplines particularly in the field of pharmaceutical spray drying and drug delivery. This knowledge has been used in the successful development of a number of pharmaceutical products from early research to testing on patients.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering:

• Greater collaboration and alliance between smaller, specialist early phase contract service providers as a way to compete against the global one-stop-shops.
• Increased demand for nasal and pulmonary delivery as a result oft the pandemic. And why Richard was not surprised to see a Covid-19 vaccine developed so quickly.
• The contrast of founding a steady 20-year growth business and the another that exited in just five years.
• The increasing demand and application for spray drying technology to solve modern pharmaceutical development challenges.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Lee Ph.D., President at the CDMO Division of Lubrizol Life Science Health (LLS). Rob has over 30 years’ experience in the pharmaceutical R&D space and his areas of expertise include drug delivery, formulation development, analytical sciences and sterile manufacturing. With a Ph.D. in Physical Bioorganic Chemistry, Rob has published more than three dozen articles and five book chapters. Plus, he holds 11 issued patents and 15 provisional or PCT patent applications. He has worked for some major companies in the sector and was appointed President of the CDMO Division of LLS after 10 years with the business.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob Lee, covering the new paradigm for drug development and manufacturing after the speed to market achieved by the COVID-19 vaccines. Rob then explains how patient-friendly dosage forms will continue to play an increasingly important role in the future. Rob also gives us an idea of the types of molecules and projects coming through the pipeline at the moment and what is in store for LLS. Lastly Rob shares what it’s been like to transition from a scientist to a leader while keeping science at the heart of everything he does. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Vice President of Life Sciences at Egnyte and the founder of the Biotech 2050 podcast. Alok has a very impressive academic and entrepreneurial background in life sciences, before running the fast-growing life science division at Egnyte, he was a Co-Founder of PreScouter and TetraScience, raising millions along the way. Having completed a postdoctoral fellowship at Harvard University, he has also been published in Forbes and Nature.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole loaf more) with Alok, covering how he founded, built and scaled two life science software companies… and then did it all over again as a vertical of a larger organisation. Alok shares the lessons he learned while raising millions in VC capital and the value of building relationships early on. He explains how CDMOs and CROs can become more strategic with biotech clients by seeing themselves as data and knowhow specialists. Finally, Raman and Alok discuss the journey of the contract services space and how the landscape has shifted from a largely transactional rigid business to becoming the foundational bedrock of the life science domain. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, we do things a little differently with an experimental episode. You’ll go inside the outsourcing space of the global drug development sector with the best-selling sales author, Ian Altman. 

Ian started, sold, and grew his prior companies from zero to over one billion dollars in value. He’s a co-author of the bestseller, Same Side Selling, now in its second edition. He is the author of hundreds of articles on Forbes and Inc. Ian is recognized as one of the world’s Top 30 Global Gurus on Sales, and his Same Side Selling Academy is ranked in the top 5 globally for Sales Development Programs.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Ian Altman discussing “becoming a magnet for your client’s problem” while also making sure the client has a problem worth solving. Ian speaks on the importance of role-playing, practising and rehearsing sales scenarios. He explains the need to aim for the ‘engage’ level with potential clients in order to secure the next pharma or biotech deal. Lastly, Ian explains the importance of understanding your client’s Elevator Rant and the emotion and impact of not solving their issue.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marco Chiado’ Piat, President, at Terumo Pharmaceutical Solutions part of Terumo. Marco has worked in the pharma and healthcare sector since the early 1990s. His impressive experience has included eight years at McKinsey before he founded a VC business. He then had several senior roles at medical device specialist LivaNova before joining Terumo Pharmaceutical Solutions in 2017, where he has risen to the top. If that was not enough, he’s an accomplished marathon runner and runs a winery in Northern Italy with his brother.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Marco Chiado’ Piat covering the importance of passion, curiosity and simply liking what you do as important pillars for serving your purpose. Marco explains how running marathons and ultra marathons has not only helped train his body for resistance but has also trained his mind for resilience. He tells Raman of the unrest Covid has caused medical device companies, and the apparent value of long term thinking that is inherent in the pharmaceutical sector. Marco closes with the importance of being ready for the unknown and unforeseen by having an ‘agility muscle’ ready to flex into action.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this one hour special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Miller. If you’ve worked in the bio and pharmaceutical CDMO space for a few years, then there’s a very good chance you will know my guest today. Jim is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering how his husband & wife start-up business helped put the industry on the map while providing CMOs/CDMOs with invaluable drug pipeline intel. He explains how CDMOs have enabled the success of the explosion of emerging biopharma in the last 10 years, helping them turn IP into product. He also gives his expert take on the changing role of CDMOs in Asia and whether we will see any APIs bounce back to North America and Europe. Lastly he covers the robustness of the market post Covid-19 and whether to expect to see a financial dip or not.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with... Raman Sehgal, founder of ramarketing and the Molecule to Market podcast.

Your host, Raman shares ten trends that he expects to see in 2021 and beyond based on themes from podcast interviews and expert insights gathered in 2020.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tia Lyles-Williams, CEO of LucasPye Bio. Tia is the first African-American Queer Woman to own & lead a Biopharma Large-Scale Manufacturing Company in the US. She has spent 20 years in the industry formerly working for the U.S. Federal Government, Big Pharma and Small Biotech Companies, before setting up her own CDMO. Tia is not only highly knowledgeable about the biotechnology sector but she works hard on helping economic development in underserved communities.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tia, covering how equality and diversity in the pharma and biotech space is no better now than it was 20 years ago, which is being compounded by Covid-19. She describes the challenges of fundraising and getting a biotech CDMO built and off the ground in an economically underserved community in Philadelphia. She stresses the importance in young people taking their education and experience into their own hands and going the extra mile to unlock new opportunities, “don’t ask permission to lead” she says. Lastly, Tia speaks on creating a new breed of CDMOs, organizations that are highly digital, leaner, faster, cheaper, and more transparent with a social conscience. She also wants to put Pennsylvania on the map as the next major global life science biotech hub.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Roger Lias, Chief Executive Officer at Stelis Biopharma. A fellow-Brit, Roger is a graduate of the University of Southampton. He also holds a PhD in Biotechnology from the University of Cambridge. His experience of the biopharma CDMO space in particular spans over 30 years including roles with the likes of Lonza, Diosynth, KBI Biopharma, Cytovance Biologics, Eden Biodesign, Allergen and Avid Bioservices and of course, Stelis. During the early part of his career, he moved to North America and now lives in California. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole load more) with Roger, covering an incredible 30 year journey at the heart of the biologic drug development explosion, including roles with the 'who’s who' of large molecule CDMOs. Roger speaks about what it was like creating a biologics CMO from the ground-up in the 90s with no obvious market. Raman and Roger discuss the value of being curious, energetic, open-minded and simply building relationships as the pillars to a long, successful career in the outsourcing space. Lastly, Roger speaks on the trend towards a closer collaboration between CDMO competitors, after all, nobody can do everything.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Quick, Executive Vice President, Corporate Development at Recipharm. In the decade that Mark and Raman have known each other, Mark has risen from a BD role in a small Swedish CMO, to becoming one of the key leaders in a business that has transitioned into becoming one of the top global CDMOs, where Mark has spearheaded the M&A deals. A graduate in Industrial Studies, Mark also did an MBA before joining Recipharm in 2006. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest (and a whole loaf more) with Mark as he explains what it’s been like growing a company from 600 - 9000 people, lifting the lid on CDMO M&A deals (having done 20+ transactions over the past 14 years), who gets involved, red flags to look out for and when you just know it’s a good fit. Mark explains how investing in relationships, embracing diversity and being open to new connections has helped him propel his career in the outsourcing space. He speaks about COVID-19 and how it has impacted a global CDMO in its different phases, including the operational impact of having sites in India and Italy. Lastly, Mark and Raman discuss continued consolidation in the sector and the increasing demand for sterile drug products with supply constraints and COVID-19 vaccines jumping the line.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stefan Beyer, President and Managing Director at Vibalogics and Tom Hochuli, Chief Executive Officer at Vibalogics. Who is this dynamic duo you ask? Stefan has spent the bulk of his career in the vaccines and biologics space. He has been head of Vibalogics for almost 13 years, steering the company from a local startup, to global CDMO and world leader in the production of virotherapy products and oncolytic vaccines. Tom has over 25 years experience in the sector and prior to Vibalogics, he headed the cell and gene therapy operations for Lonza Houston. Today, Tom is responsible for Vibalogics’ U.S. expansion plans as the company sets its sights on developing a late phase and commercial virus manufacturing facility on the East Coast, U.S.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guests Stefan and Tom, covering the boom in virotherapy capabilities such as oncolytic viruses, viral vector gene therapies and viral vector vaccines over the past decade. Tom discusses the lessons he’s learned from being a platoon leader in the US Army to leading teams in business. Tom and Stefan explain how as a leader, it is important to have an open mind when it comes to exploring new opportunities and ideas and accepting failure as a part of success and learning. Lastly we explore the short-term impact that Covid-19 has had on delaying promising pipelines and compounds currently in clinical trials. We look ahead to the longer-term impact it will have on refocusing drug developers’ attention on the need for vaccines, and being better prepared in the case of an infectious outbreak. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Dexter Tjoa, Chief Executive Officer at Tjoapack, Erik Haeffler, VP Manufacturing Services & Head of Sustainability at Recipharm AB, John Ross, President at Mayne Pharma and Metrics Contract Services, and Mark Emalfarb, CEO, Board Member and Founder at Dyadic International, Inc.

During this discussion we will explore two angles to driving efficiency, diversification vs. development of specialism. Emerging trends include the move to manufacture multiple technologies under one roof, at the other end of the scale we see companies staying true to original areas of expertise in order to refine and grow.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences. 

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Roger Lias Chief Executive Officer at Stelis Biopharma Pvt. Ltd. and Stelis Biopharma LLC, Mark Quick, Executive Vice President Corporate Development at Recipharm AB, Lynn Allen, Vice President Of Business Development at MedPharm Ltd, Alfredo Gomez, Head of Site at Idifarma, and Rick Seibert, Sr. Vice President, Innovation and Technology Services at Sharp Clinical Services.

This session will involve a wider discussion around COVID-19 related trends and also natural progression in the CDMO space. We will begin by exploring recurring trends involving futureproofing and digitisation across the industry including a growing need for automation.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Torkel Gren, Senior Director, Technology Officer & Strategic Investments at Recipharm, Sascha Sonnenberg, Global Head of Business Development at Sharp Clinical Services, Vincent Dunne, CEO at Wasdell Group and Stephen Rode, Business Development Manager for Lonza Pharma and Biotech.

We’ll explore the impact of COVID-19 on traditional clinical trial processes to highlight how the industry has adapted. We will cover topics including ‘direct to patient treatment’ and trends that highlight a move away from the ‘norm’ in order to survive and thrive.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Erik Haeffler, VP Manufacturing Services & Head of Sustainability at Recipharm AB, Dan Stanton, Founder and Editor of Bioprocess Insider and Stefano Console, Senior Advisor and Founder at Oriento.

Join us as we discuss the impact of COVID-19 on the pharma and bio supply chain. We explore the real human challenges experienced in the face of a global pandemic and the impact these challenges have had on business. We also discuss concerns around safety and environmental impacts relating to materials suppliers.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Shane Needham, Chief Founding Scientist, Director of the Board and Owner at Alturas Analytics, Inc. With a PHD in chemistry, Dr. Needham has spent almost 30 years in the sector. He started his career at Pfizer and went on to found his own company, Alturas Analytics, which focuses on solving complex bioanalytical problems. He has over 100 publications and external presentations in the area of LC/MS and leads a team of world class scientists. And if this isn’t impressive enough, beyond work, Shane is a podcaster, TEDx motivational speaker, champion bodybuilder, champion powerlifter and philanthropist. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole loaf more) with Shane, covering the importance of coaching as a leader and setting the best example you can. Shane gives listeners life lessons in relationships, giving it your all, and in succeeding and failing. Raman and Shane speak about the impact of Covid-19 in accelerating the ‘things that would have happened eventually’ in the pharma and biotech analytical testing space. And finally Shane speaks on the parallels between success in business and success in hobbies, we’ll give you a hint, consistency is the most important factor.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason Lacombe, CEO at Veratrak. A graduate of Toronto and Oxford University, Jason was recently named as one of Forbes 30 Under 30 and has also advised the WHO and EU. Today, his business is one of the fastest growing tech companies in the life science space.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering the impact Covid-19 has had on accelerating the digitisation of the global pharmaceutical supply chain. Jason speaks about dealing with inertia and how it is now more clear than ever; the old way of doing things is not fit for our modern world. Lastly, Jason touches on the importance of aiming for less stock outs, faster leader times, more secure documentation and most importantly, better patient outcomes. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics. To say Mary has an impressive track record is an understatement. Across the last three decades she has worked for some of the biggest pharmaceutical companies in the world including Janssen and Bristol Myers Squibb before moving onto several fast growing biotech companies including Ironwood, Cyclerion and now Lyndra in senior regulatory and quality roles. She’s also a guest lecturer, a mentor to many, and a trustee for the Center for Great Expectations in New Jersey. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Mary Christian. In this episode, Mary reflects on the main differences in working with small, nimble bio and pharma companies compared to larger more structured organizations, particularly commenting on the different ways vendors are selected. She also addressed the major shift in types of relationships sponsors and vendors have with each other as she has seen things become less transactional over time. She gives valuable advice to vendors on how to get the most out of your partnership from the very beginning while explaining what a good and bad partnership experience looks like from her perspective as a sponsor. Mary gives advice based on her experience as a successful leader in the space and explains the value in having a support system at work and at home. She also highlights how important it is, for women especially, to not opt out of opportunities to further their career. Lastly Mary speaks about The Center for Great Expectations, an organization which empowers women and families battling mental health and substance disorders to break the cycle and provide better lives for their children.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sara Lesina, Global Marketing Director of Pharma & Nutrition, Capsules and Health Ingredients at Lonza. A multilingual, international marketing leader, Sara oversees the global marketing and product line management team for the capsule business of Lonza, Capsugel®.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Sara Lesina, covering how diversity in her life and career has given her a much more open, flexible and balanced view of the world and how it has helped her as a leader in a global pharma industry. Sara also explains the value of learning from failure and how making mistakes is part of the journey in stretching yourself to become a bolder and more confident individual. Lastly, Raman and Sara discuss the impact that COVID-19 has had on business and marketing efforts in the pharmaceutical and biotech space, making it clear that traditional solutions will not provide answers for the current and future challenges we face.

Please subscribe, and invite your industry colleagues to join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Carl-Åke Carlsson CEO at Xellia Pharmaceuticals. Like celebrated “one-club” football stars like Leo Messi at Barcelona, Alessandro Del Piero at Juventus and Steven Gerrard at Liverpool… Carl-Åke has been with Xellia since 1988. A pharmaceutical leader known for his class and commercial acumen, Carl‑Åke started in a finance position. He was soon diversifying into other areas and running various divisions before rising to the top as global CEO of a business that employs 1,800 people.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke Carlsson, covering Xellia’s journey from an API supplier to a global specialty pharma company known for novel anti-infective, life-saving medicines. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years, offering advice and insight from his experiences. He explains how he has created and scaled a world-class culture using internal, cross-functional “transformers” to assist in upholding values internally and externally. He speaks about the origins of the industry-renowned DCAT and CPhI Xellia parties. And lastly, he announces some exciting news about Xellia and their plans for expansion.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Manuel Leal, Business Development Director at IDIFARMA. A student of law and business, Manuel has carved a very impressive career in the outsourcing space all despite having no formal pharma and science background! He has spent the last decade helping take a little known, local formulation development firm in Northern Spain into a global, specialist CDMO.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Manuel, covering the transition from development and clinical manufacturing to commercial production. Manuel gives us the inside scoop on what it’s like being a boutique, niche CDMO with in-demand high potency and spray drying capabilities versus serving as a “one-stop-shop”. He discusses the value of curiosity, resilience, continuous learning and being humble in carving a career in pharma, and how he has found success without a science background. Lastly, Raman and Manuel speak on the reasons we may see geographically closer and more controlled supply chains in the post Covid-19 world.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Thompson, CEO and Founder at Agility Life Sciences. Claire is an award winning pharmaceutical scientist with over 20 years of experience in developing pharma products, global companies, virtual biotechs and CROs. Today, Claire consults global health companies ranging from spin outs to multinational companies on how to fast track their technology to market. Claire has worked for Pfizer, GSK, Oxford, Pharma Science and The Royal Pharma Society to name a few. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering the value of standing out in a crowd, being memorable and owning your authenticity, especially as a female in the pharma and biotech sector. Claire shares what she has learned from playing elite level football for many years and how she has been able to apply these lessons to business strategy, communications, winning and being a team. She and Raman also discuss a continued trend in outsourcing growth, with biotech companies opting for parallel manufacturing with CDMOs to mitigate risk in reaching key milestones. Lastly Claire champions several notable female causes and Raman makes a live donation on air!

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kevin Orfan, President at Sharp. Kevin has been in the pharmaceutical and medical device industry for over 30 years and has incredible experience in the contract manufacturing space. He began his pharma career at Abbott Laboratories before moving to Hospira and then Pfizer CentreOne. He joined Sharp as president in 2019 and now oversees its global operations.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Kevin Orfan speaking on the importance of building robust and scalable systems and processes in a fast growing contract packaging company, especially in the current climate of the pandemic. Kevin talks about the challenges in keeping up with the rapid, global demand of new, large molecule drug products and the increasing complexity they bring. He shares how he maintains a solid work ethic by always having a plan, knowing what he can control and focusing on the value-add factors in a business as a top priority. Lastly he speaks about the direct-to-patient trend he is seeing in the industry as pharmaceutical companies become more willing to carry out clinical trial work in patient's homes.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeffrey Kiplinger, Co-Founder of Cohere Business Strategies and advisor and coach for entrepreneurs in the life science space. Jeffrey Co-Founded Research Operations Group in 2000, founded Averica Discovery Services in 2007, and has over 35 academic publications and holds a PhD in organic chemistry. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Jeffrey Kiplinger as he describes the benefit in making oneself vulnerable and putting your pride aside to seek the support of others. He advises young leaders to ask “stupid questions” and allow your mistakes to become a part of your success story. Jeffrey speaks about the changes he has seen in the sector over the years and the interesting shift towards a numbers-based system which in his opinion, has devalued the scientists at the core of operations. As a coach for entrepreneurs, Jeff covers the barriers many business professionals face when trying to start their own business in the life science sector. He offers advice and words of wisdom for those who are struggling in this difficult market. Lastly he stresses the value of the relationship with a client and explains how it can be the key to success in this industry.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gil Roth, Founder and President of the Pharma & Biopharma Outsourcing Association (PBOA). Previous to launching PBOA in 2014, Gil helped launch Contract Pharma in 1999 and served as the founding editor for 15 years. Contract Pharma has since grown to become one of the most respected magazines in the industry.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Gil Roth, speaking on the tremendous impact the PBOA has made with congress and the FDA on behalf of the contract manufacturing industry. Gil offers some insight on how the PBOA has found success in influencing representatives and senators in Washington to learn about the sector and advocate on its behalf. Gil reflects on the ways the industry has changed over the past couple of decades, such as the sophistication of acquisitions and the willingness to openly outsource from a reputation standpoint. Raman and Gil identify the trends and challenges they have noticed in a time where once common business practices have been stripped away as we all adapt to this new normal. Lastly Gil speaks about his own podcast, The Virtual Memories Show, and the impact and joy it has created over the years. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.